

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

**EP 1 166 798 A1**

(12)

**EUROPEAN PATENT APPLICATION**

(43) Date of publication:

02.01.2002 Bulletin 2002/01

(51) Int Cl.7: **A61K 45/06**

(21) Application number: 00250194.8

(22) Date of filing: 23.06.2000

(84) Designated Contracting States:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE

Designated Extension States:

AL LT LV MK RO SI

(71) Applicant: **Schering Aktiengesellschaft**  
13353 Berlin (DE)

(72) Inventors:

- Siemeister, Gerhard  
13503 Berlin (DE)
- Haberey, Martin, Dr.  
12169 Berlin (DE)
- Thierauch, Karl-Heinz, Dr.  
14169 Berlin (DE)

(54) **Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/ Tie receptor function and their use**

(57) The present invention describes the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)NEGF re-

ceptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

**BEST AVAILABLE COPY**

**EP 1 166 798 A1**

## Description

[0001] The present invention provides the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

[0002] Protein ligands and receptor tyrosine kinases that specifically regulate endothelial cell function are substantially involved in physiological as well as in disease-related angiogenesis. These ligand/receptor systems include the Vascular Endothelial Growth Factor (VEGF) and the Angiopoietin (Ang) families, and their receptors, the VEGF receptor family and the tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (Tie) family. The members of the two families of receptor tyrosine kinases are expressed primarily on endothelial cells. The VEGF receptor family includes Flt1 (VEGF-R1), Flk1/KDR (VEGF-R2), and Flt4 (VEGF-R3). These receptors are recognized by members of the VEGF-related growth factors in that the ligands of Flt1 are VEGF and placenta growth factor (PlGF), whereas Flk1/KDR binds VEGF, VEGF-C and VEGF-D, and the ligands of Flt4 are VEGF-C and VEGF-D (Nicosia, Am. J. Pathol. 153, 11-16, 1998). The second family of endothelial cell specific receptor tyrosine kinases is represented by Tie1 and Tie2 (also known as Tek). Whereas Tie1 remains an orphan receptor, three secreted glycoprotein ligands of Tie2, Ang1, Ang2, and Ang3/Ang4 have been discovered (Davis et al., Cell 87, 1161-1169, 1996; Maisonpierre et al., Science 277, 55-60, 1997; Valenzuela et al., Proc. Natl. Acad. Sci. USA 96, 1904-1909, 1999; patents: US 5,521,073; US 5,650,490; US 5,814,464).

[0003] The pivotal role of VEGF and of its receptors during vascular development was exemplified in studies on targeted gene inactivation. Even the heterozygous disruption of the VEGF gene resulted in fatal deficiencies in vascularization (Carmeliet et al., Nature 380, 435-439, 1996; Ferrara et al., Nature 380, 439-442, 1996). Mice carrying homozygous disruptions in either Flt1 or Flk1/KDR gene die in mid-gestation of acute vascular defects. However, the phenotypes are distinct in that Flk1/KDR knock-out mice lack both endothelial cells and a developing hematopoietic system (Shalaby et al., Nature 376, 62-66, 1995), whereas Flt1 deficient mice have normal hematopoietic progenitors and endothelial cells, which fail to assemble into functional vessels (Fong et al., 376, 66-70, 1995). Disruption of the Flt4 gene, whose extensive embryonic expression becomes restricted to lymphatic vessels in adults, revealed an essential role of Flt4 for the remodeling and maturation of the primary vascular networks into larger blood vessels during early development of the cardiovascular system (Dumont et al., Science 282, 946-949, 1998). Consistent with the lymphatic expression of Flt4 in adults overexpression of VEGF-C in the skin of transgenic mice resulted in lymphatic, but not vascular, endothelial proliferation and vessel enlargement (Jeltsch et al., Science 276, 1423-1425, 1997). Moreover, VEGF-C was reported to induce neovascularization in mouse cornea and chicken embryo chorioallantoic membrane models of angiogenesis (Cao et al., Proc. Natl. Acad. Sci. USA 95, 14389-14394, 1998).

[0004] The second class of endothelial cell specific receptor tyrosine kinases has also been found to be critically involved in the formation and integrity of vasculature. Mice deficient in Tie1 die of edema and hemorrhage resulting from poor structural integrity of endothelial cells of the microvasculature (Sato et al., Nature 376, 70-74, 1995; Rodewald & Sato, Oncogene 12, 397-404, 1996). The Tie2 knock-out phenotype is characterized by immature vessels lacking branching networks and lacking periendothelial support cells (Sato et al., Nature 376, 70-74, 1995; Dumont et al., Genes Dev. 8, 1897-1909, 1994). Targeted inactivation of the Tie2 ligand Ang1, as well as overexpression of Ang2, an inhibitory ligand, resulted in phenotypes similar to the Tie2 knock out (Maisonpierre et al., Science 277, 55-60, 1997; Suri et al., Cell 87, 1171-1180). Conversely, increased vascularization was observed upon transgenic overexpression of Ang1 (Suri et al., Science 282, 468-471, 1998; Thurston et al., Science 286, 2511-2514, 1999).

[0005] The results from angiogenic growth factor expression studies in corpus luteum development (Maisonpierre et al., Science 277, 55-60, 1997; Goede et al., Lab. Invest. 78, 1385-1394, 1998), studies on blood vessel maturation in the retina (Alon et al., Nature Med. 1, 1024-1028, 1995; Benjamin et al., Development 125, 1591-1598, 1998), and gene targeting and transgenic experiments on Tie2, Ang1, and Ang2, suggest a fundamental role of the Angiopoietin/Tie receptor system in mediating interactions between endothelial cells and surrounding pericytes or smooth muscle cells. Ang1, which is expressed by the periendothelial cells and seems to be expressed constitutively in the adult, is thought to stabilize existing mature vessels. Ang2, the natural antagonist of Ang1 which is expressed by endothelial cells at sites of vessel sprouting, seems to mediate loosening of endothelial-periendothelial cell contacts to allow vascular remodeling and sprouting in cooperation with angiogenesis initiators such as VEGF, or vessel regression in the absence of VEGF (Hanahan, Science 277, 48-50, 1997).

[0006] In pathological settings associated with aberrant neovascularization elevated expression of angiogenic growth factors and of their receptors has been observed. Most solid tumors express high levels of VEGF and the VEGF receptors appear predominantly in endothelial cells of vessels surrounding or penetrating the malignant tissue (Plate et al., Cancer Res. 53, 5822-5827, 1993). Interference with the VEGF/VEGF receptor system by means of VEGF-neutralizing antibodies (Kim et al., Nature 362, 841-844, 1993), retroviral expression of dominant negative VEGF receptor variants (Millauer et al., Nature 367, 576-579, 1994), recombinant VEGF-neutralizing receptor variants (Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998), or small molecule inhibitors of VEGF receptor tyrosine

kinase (Fong et al., *Cancer Res.* 59, 99-106, 1999; Wedge et al., *Cancer Res.* 60, 970-975, 2000; Wood et al. *Cancer Res.* 60, 2178-2189, 2000), or targeting cytotoxic agents via the VEGF/VEGF receptor system (Arora et al., *Cancer Res.* 59, 183-188, 1999; EP 0696456A2) resulted in reduced tumor growth and tumor vascularization. However, although many tumors were inhibited by interference with the VEGF/VEGF receptor system, others were unaffected (Millauer et al., *Cancer Res.* 56, 1615-1620, 1996). Human tumors as well as experimental tumor xenografts contain a large number of immature blood vessels that have not yet recruited periendothelial cells. The fraction of immature vessels is in the range of 40% in slow growing prostate cancer and 90% in fast growing glioblastoma. A selective obliteration of immature tumor vessels was observed upon withdrawal of VEGF by means of downregulation of VEGF transgene expression in a C6 glioblastoma xenograft model. This result is in accordance with a function of VEGF as endothelial cell survival factor. Similarly, in human prostate cancer shutting off VEGF expression as a consequence of androgen-ablation therapy led to selective apoptotic death of endothelial cells in vessels lacking periendothelial cell coverage. In contrast, the fraction of vessels which resisted VEGF withdrawal showed periendothelial cell coverage (Benjamin et al., *J. Clin. Invest.* 103, 159-165, 1999).

[0007] The observation of elevated expression of Tie receptors in the endothelium of metastatic melanomas (Kai-palinen et al., *Cancer Res.* 54, 6571-6577, 1994), in breast carcinomas (Salvén et al., *Br. J. Cancer* 74, 69-72, 1996), and in tumor xenografts grown in the presence of dominant-negative VEGF receptors (Millauer et al., *Cancer Res.* 56, 1615-1620, 1996), as well as elevated expression of Flt4 receptors in the endothelium of lymphatic vessels surrounding lymphomas and breast carcinomas (Jussila et al., *Cancer Res.* 58, 1599-1604, 1998), and of VEGF-C in various human tumor samples (Salvén et al., *Am. J. Pathol.* 153, 103-108, 1998), suggested these endothelium-specific growth factors and receptors as candidate alternative pathways driving tumor neovascularization. The high upregulation of Ang2 expression already in early tumors has been interpreted in terms of a host defense mechanism against initial cooption of existing blood vessels by the developing tumor. In the absence of VEGF, the coopted vessels undergo regression leading to necrosis within the center of the tumor. Contrarily, hypoxic upregulation of VEGF expression in cooperation with elevated Ang2 expression rescues and supports tumor vascularization and tumor growth at the tumor margin (Holash et al., *Science* 284, 1994-1998, 1999; Holash et al., *Oncogene* 18, 5356-5362, 1999).

[0008] Interference with Tie2 receptor function by means of Angiopoietin-neutralizing Tie2 variants consisting of the extracellular ligand-binding domain has been shown to result in inhibition of growth and vascularization of experimental tumors (Lin et al., *J. Clin. Invest.* 103, 159-165, 1999; Lin et al. *Proc. Natl. Acad. Sci. USA* 95, 8829-8834, 1998; Siemeister et al., *Cancer Res.* 59, 3185-3191, 1999). Comparing the effects of interference with the endothelium-specific receptor tyrosine kinase pathways by means of paracrine expression of the respective extracellular receptor domains on the same cellular background demonstrated inhibition of tumor growth upon blockade of the VEGF receptor system and of the Tie2 receptor system, respectively (Siemeister et al., *Cancer Res.* 59, 3185-3191, 1999).

It is known that the inhibition of the VEGF/VEGR receptor system by various methods resulted only in slowing down growth of most experimental tumors (Millauer et al., *Nature* 367, 576-579, 1994; Kim et al., *Nature* 362, 841-844, 1993; Millauer et al., *Cancer Res.* 56, 1615-1620, 1996; Goldman et al., *Proc. Natl. Acad. Sci. USA* 95, 8795-8800, 1998; Fong et al., *Cancer Res.* 59, 99-106, 1999; Wedge et al., *Cancer Res.* 60, 970-975, 2000; Wood et al. *Cancer Res.* 60, 2178-2189, 2000; Siemeister et al., *Cancer Res.* 59, 3185-3191, 1999). Even by escalation of therapeutic doses a plateau level of therapeutic efficacy was achieved (Kim et al., *Nature* 362, 841-844, 1993; Wood et al. *Cancer Res.* 60, 2178-2189, 2000). Similar results were observed upon interference with the Angiopoietin/Tie2 receptor system (Lin et al., *J. Clin. Invest.* 103, 159-165, 1999; Lin et al., *Proc. Natl. Acad. Sci. USA* 95, 8829-8834, 1998; Siemeister et al., *Cancer Res.* 59, 3185-3191, 1999).

[0009] However, there is a high demand for methods that enhance the therapeutic efficacy of anti-angiogenous compounds.

[0010] Searching for methods that enhance the therapeutic efficacy of anti-angiogenic compounds, superior anti-tumor effects were observed unexpectedly upon combination of inhibition of VEGF/VEGF receptor systems and interference with biological function of Angiopoietin/Tie receptor systems. The mode of action underlying the superior effects observed may be that interference biological function of Angiopoietin/Tie receptor systems destabilizes endothelial cell-periendothelial cell interaction of existing mature tumor vessels and thereby sensitizes the endothelium to compounds directed against VEGF/VEGF receptor systems.

[0011] Based on this unexpected finding the present invention provides the combination of functional interference with VEGF/VEGF receptor systems and with Angiopoietin/Tie receptor systems for inhibition of vascularization and of tumor growth.

The pharmaceutical composition consists of two components: compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of VEGF/VEGF receptor systems. Compound II interferes with the biological function of one or several of Angiopoietin/Tie receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of Angiopoietin/Tie receptor systems. Alternatively, compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems and compound II consists of cytotoxic

agents which are targeted to the endothelium via recognition of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems. Targeting or modulation of the biological activities of VEGF/VEGF receptor systems and of Angiopoietin/Tie receptor systems can be performed by

- (a) compounds which inhibit receptor tyrosine kinase activity,
- (b) compounds which inhibit ligand binding to receptors,
- (c) compounds which inhibit activation of intracellular signal pathways of the receptors,
- (d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- (e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- (f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.


**[0012]** A compound comprised by compositions of the present invention can be a small molecular weight substance, an oligonucleotide, an oligopeptide, a recombinant protein, an antibody, or conjugates or fusionproteins thereof. An example of an inhibitor is a small molecular weight molecule which inactivates a receptor tyrosine kinase by binding to and occupying the catalytic site such that the biological activity of the receptor is decreased. Kinase inhibitors are known in the art (Sugen: SU5416, SU6668; Fong et al. (1999), *Cancer Res.* 59, 99-106; Vajkoczy et al., *Proc. Am. Assoc. Cancer Res. San Francisco* (2000), Abstract ID 3612; Zeneca: ZD4190, ZD6474; Wedge et al. (2000), *Cancer Res.* 60, 970-975; Parke-Davis PD0173073, PD0173074; Johnson et al., *Proc. Am. Assoc. Cancer Res., San Francisco* (2000), Abstract ID 3614; Dimitroff et al. (1999), *Invest. New Drugs* 17, 121-135). An example of an antagonist is a recombinant protein or an antibody which binds to a ligand such that activation of the receptor by the ligand is prevented. Another example of an antagonist is an antibody which binds to the receptor such that activation of the receptor is prevented. An example of an expression modulator is an antisense RNA or ribozyme which controls expression of a ligand or a receptor. An example of a targeted cytotoxic agent is a fusion protein of a ligand with a bacterial or plant toxin such as *Pseudomonas* exotoxin A, Diphtheria toxin, or Ricin A. An example of a targeted coagulation-inducing agent is a conjugate of a single chain antibody and tissue factor. Ligand-binding inhibitors such as neutralizing antibodies which are known in the art are described by Genentech (rhvMAbVEGF) and by Presta et al. (1997), *Cancer Res.* 57, 4593-4599. Ligand-binding receptor domains are described by Kendall & Thomas (1993), *Proc. Natl. Acad. Sci., U.S.A.* 90, 10705-10709; by Goldman et al. (1998) *Proc. Natl. Acad. Sci., U.S.A.* 95, 8795-8800 and by Lin et al. (1997), *J. Clin. Invest.* 100, 2072-2078. Further, dominant negative receptors have been described by Millauer et al. (1994), *Nature* 367, 567-579.

Receptor blocking antibodies have been described by Imclone (c-p1C11, US 5,874,542). Further known are antagonistic ligand mutants (Siemeister et al. (1998), *Proc. Natl. Acad. Sci., U.S.A.* 95, 4625-4629). High affinity ligand- or receptor binding oligo nucleotides have been described by NeXstar (NX-244) and Drolet et al. (1996), *Nat. Biotech.* 14, 1021-1025. Further, small molecules and peptides have been described.

**[0013]** Expression regulators have been described as anti-sense oligo nucleotides and as ribozymes (RPI, Angiozyme™, see RPI Homepage).

**[0014]** Examples for delivery-/Targeting-Systems have been described as ligand/ antibody-toxin-fusion-proteins or conjugates (Arora et al. (1999), *Cancer Res.* 59, 183-188 and Olson et al. (1997), *Int. J. Cancer* 73, 865-870), as endothelial cell targeting of liposomes (Spragg et al. (1997), *Prog. Natl. Acad. Sci., U.S.A.* 94, 8795-8800, and as endothelial cell targeting plus coagulation-induction (Ran et al., (1998), *Cancer Res.* 58, 4646-4653).

**[0015]** Small molecules which inhibit the receptor tyrosine kinase activity are for example molecules of general formula I



in which


$r$   
 $n$   
 $R_3$  und  $R_4$

has the meaning of 0 to 2,

has the meaning of 0 to 2;

a) each independently from each other have the meaning of lower alkyl,


b) together form a bridge of general partial formula II,



wherein the binding is via the two terminal C- atoms, and

has the meaning of 0 to 4; or

c) together form a bridge of partial formula III



wherein one or two of the ring members  $T_1, T_2, T_3, T_4$  has the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms  $T_1$  and  $T_4$ ;

$G$  has the meaning of  $C_1 - C_6$  - alkyl,  $C_2 - C_6$  - alkylene or  $C_2 - C_6$  - alkenylene; or  $C_2 - C_6$  - alkylene or  $C_3 - C_6$  - alkenylene, which are substituted with acyloxy or hydroxy;  $-CH_2-O-$ ,  $-CH_2-S-$ ,  $-CH_2-NH-$ ,  $-CH_2-O-CH_2-$ ,  $-CH_2-S-CH_2-$ ,  $-CH_2-NH-CH_2-$ , oxa ( $-O-$ ), thia ( $-S-$ ) or imino ( $-NH-$ ),

$A, B, D, E$  and  $T$  independently from each other have the meaning of N or CH, with the provsio that not more than three of these Substituents have the meaning of N,


$Q$  has the meaning of lower alkyl, lower alkyloxy or halogene,

$R_1$  and  $R_2$  independently from each other have the meaning of H or lower alkyl,  
 $X$  has the meaning of imino, oxa or thia;  
 $Y$  has the meaning of hydrogen, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and  
 $Z$  has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherified or esterified hydroxy, nitro, cyano, carboxy, esterified carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if more than one rest  $Z$  is present ( $m \geq 2$ ), the substituents  $Z$  are equal or different from each other, and wherein the bonds marked with an arrow are single or double bonds; or an N-oxide of said compound, wherein one or more N-atoms carry an oxygen atom, or a salt thereof.

[0016] A preferred salt is the salt of an organic acid, especially a succinate.


[0017] These compounds can preferentially be used as compound I or II in the inventive pharmaceutical composition.

[0018] Compounds which stop a tyrosin phosphorylation, or the persistent angiogenesis, respectively, which results in a prevention of tumor growth and tumor spread, are for example anthranil acid derivatives of general formula IV




In which

$A$  has the meaning of group  $=NR^2$ ,  
 $W$  has the meaning of oxygen, sulfur, two hydrogen atoms or the group  $=NR^8$ ,  
 $Z$  has the meaning of the group  $=NR^{10}$  or  $=N-$ ,  $-N(R^{10})-(CH_2)_q$ , branched or unbranched  $C_{1-6}$ -Alkyl or is the group



or  $A$ ,  $Z$  and  $R^1$  together form the group



m, n and o

q

 $R_a, R_b, R_c, R_d, R_e, R_f$ 

X

Y

P


 $R^1$  $R^2$  $R^3$  $R^4, R^5, R^6$  and  $R^7$ 

has the meaning of 0 - 3,

has the meaning of 1 - 6,


independently from each other have the meaning of hydrogen,  $C_{1-4}$  alkyl or the group  $=NR^{10}$ , and/ or  $R_a$  and/ or  $R_b$  together with  $R_c$  and or  $R_d$  or  $R_c$  together with  $R_e$  and/ or  $R_f$  form a bound, or up to two of the groups  $R_a-R_f$  form a bridge with each up to 3 C-atoms with  $R^1$  or  $R^2$ ,has the meaning of group  $=NR^9$  or  $=N-$ ,has the meaning of group  $-(CH_2)_p$ ,

has the meaning of integer 1-4,

has the meaning of unsubstituted or optionally substituted with one or more of halogene,  $C_{1-6}$ -alkyl, or  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,has the meaning of hydrogen or  $C_{1-6}$ -alkyl, or form a bridge with up to 3 ring atoms with  $R_a-R_f$  together with Z or  $R^1$ ,has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally substituted with one or more of für halogen,  $C_{1-6}$ -alkyl,  $C_{1-6}$ -alkoxy or hydroxy,independently from each other have the meaning of hydrogen, halogen or  $C_{1-6}$ -alkoxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogen, or  $R^5$  and  $R^6$  together form the group $R^8, R^9$  and  $R^{10}$ independently from each other have the meaning of hydrogen or  $C_{1-6}$ -alkyl, as well as their isomers and salts.

[0019] These compounds can also preferentially be used as compound I or II in the inventive pharmaceutical composition.



[0020] More preferentially compounds of general formula V




V,

In which

R¹ has the meaning of group




in which R⁵ is chloro, bromo or the group -OCH₃,



in which R⁷ is -CH₃ or chloro,






in which  $R^3$  is  $-\text{CH}_3$ , fluoro, chloro or  $-\text{CF}_3$

in which  $R^4$  is fluoro, chloro, bromo,  $-\text{CF}_3$ ,  $-\text{N}=\text{C}$ ,  $-\text{CH}_3$ ,  $-\text{OCF}_3$  or  $-\text{CH}_2\text{OH}$

in which  $R^8$  is  $-\text{CH}_3$  or chloro

$R^2$  has the meaning of pyridyl or the group



and

$R^3$  has the meaning of hydrogen or fluoro, as well as their isomers and salts can be used as compound I or II in the inventive pharmaceutical composition.

[0021] These compounds have the same properties as already mentioned above under compound IV and can be used for the treatment of angiogeneous diseases. Compositions comprise compounds of general formulae I, IV and V, alone or in combination.

The above mentioned compounds are also claimed matter within the inventive combinations.

[0022] A further example for ligand binding inhibitors are peptides and DNA sequences coding for such peptides, which are used for the treatment of angiogeneous diseases. Such peptides and DNA sequences are disclosed in Seq. ID No. 1 to 59 of the sequence protocol. It has been shown that Seq. ID Nos. 34 and 34a are of main interest.

[0023] Claimed matter of the instant invention are therefor pharmaceutical compositions

a) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

b) comprising one or several agents as compound I which are targeted to the endothelium via of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

c) comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium,

d) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

e) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to

the endothelium via one or several of the Angiopoietin/Tie receptor systems,

f) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems,

g) comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems and

h) comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

**[0024]** For a sequential therapeutical application the inventive pharmaceutical compositions can be applied simultaneously or separately.

**[0025]** The inventive compositions comprise as compound I or as compound II at least one of

- a) compounds which inhibit receptor tyrosine kinase activity,
- b) compounds which inhibit ligand binding to receptors,
- c) compounds which inhibit activation of intracellular signal pathways of the receptors,
- d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

These compositions are also claimed matter of the present invention.

**[0026]** Also claimed matter of the present invention are pharmaceutical compositions which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59. Of most value are pharmaceutical compositions, which comprise as compound I and/ or II Seq. ID Nos. 34a und pharmaceutical compositions according to claims which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35 and/ or scFv-tTF conjugate.

**[0027]** Further preferred matter of the present invention are pharmaceutical compositions, which comprise as compound I and/ or II at least one small molecule of general formula I, general formula IV and/ or general formula V.

**[0028]** The most preferred compound which can be used as compound I or II in the inventive composition is (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate.

Therefore, claimed matter of the present invention are also pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35 and/ or scFv-tTF conjugate and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35 and/ or scFv-tTF conjugate, with the proviso that compound I is not identically to compound II, and most preferred pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35 and/ or scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35.

**[0029]** The small molecule compounds, proteins and DNA's expressing proteins, as mentioned above can be used as medicament alone, or in form of formulations for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis and damage of nerve tissues.

The treatment of the damaged nerve tissues with the inventive combination hinders the rapid formation of scars at the damaged position. Thus, there is no scar formation before the axons communicate with each other. Therefore a reconstruction of the nerve bindings is much more easier.

**[0030]** Further, the inventive combinations can be used for suppression of the ascites formation in patients. It is also possible to suppress VEGF oedemas.

For the use of the inventive combinations as medicament the compounds will be formulated as pharmaceutical composition. Said formulation comprises beside the active compound or compounds acceptable pharmaceutically, organ-

ically or inorganically inert carriers, such as water, gelatine, gum arabic, lactose, starch, magnesium stearate, talcum, plant oils, polyalkylene glycols, etc. Said pharmaceutical preparations can be applied in solid form, such as tablets, pills, suppositories, capsules, or can be applied in fluid form, such as solutions, suspensions or emulsions.

If necessary, the compositions additionally contain additives, such as preservatives, stabilizer, detergents or emulgators, salts for alteration of the osmotic pressure and/or buffer.

These uses are also claimed matter of the instant invention, as well as the formulations of the active compounds

[0031] For parenteral application especially injectable solutions or suspensions are suitable, especially hydrous solutions of the active compound in polyhydroxyethoxylated castor-oil are suitable.

As carrier also additives can be used, such as salts of the gallic acid or animal or plant phospholipids, as well as mixtures thereof, and liposomes or ingredients thereof.

For oral application especially suitable are tablets, pills or capsules with talcum and/or hydrocarbon carriers or binders, such as lactose, maize or potato starch.

[0032] The oral application can also be in form of a liquid, such as juice, which optionally contains a sweetener.

The dosis of the active compound differs depending on the application of the compound, age and weight of the patient, as well as the form and the progress of the disease.

The daily dosage of the active compound is 0,5-1000 mg, especially 50-200 mg. The dosis can be applied as single dose or as two or more daily dosis.

[0033] These formulations and application forms are also part of the instant invention.

[0034] Combined functional interference with VEGF/VEGF receptor systems and with Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to interference with one ligand/receptor system overlaps with the biological response to interference with a second ligand/receptor system. Alternatively, combined functional interference with VEGF/VEGF receptor systems or with Angiopoietin/Tie receptor systems and targeting of cytotoxic agents via VEGF/VEGF receptor systems or via Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to functional interference with a ligand/receptor system overlaps in time with targeting of cytotoxic agents.

[0035] The invention is also directed to a substance which functional interferes with both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems, or which are targeted via both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems.

[0036] VEGF/VEGF receptor systems include the ligands VEGF-A, VEGF-B, VEGF-C, VEGF-D, PlGF, and the receptor tyrosine kinases VEGF-R1 (Flt1), VEGF-R2 (KDR/Flk1), VEGF-R3 (Flt4), and their co-receptors (i.e. neuropilin-1). Angiopoietin/Tie receptor systems include Ang1, Ang2, Ang3/Ang4, and angiopoietin related polypeptides which bind to Tie1 or to Tie2, and the receptor tyrosine kinases Tie1 and Tie2.

[0037] Pharmaceutical compositions of the present invention can be used for medicinal purposes. Such diseases are, for example, cancer, cancer metastasis, angiogenesis including retinopathy and psoriasis. Pharmaceutical compositions of the present invention can be applied orally, parenterally, or via gene therapeutic methods.

[0038] Therefor the present invention also concerns the use of pharmaceutical compositions for the production of a medicament for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

[0039] The following example demonstrates the feasibility of the disclosed invention, without restricting the invention to the disclosed example.

#### Example 1

[0040] Superior effect on inhibition of tumor growth via combination of inhibition of the VEGF A/VEGF receptor system together with functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention was demonstrated in an A375v human melanoma xenograft model.

[0041] Human melanoma cell line A375v was stably transfected to overexpress the extracellular ligand-neutralizing domain of human Tie2 receptor tyrosine kinase (sTie2; compound II) (Siemeister et al., Cancer Res. 59, 3185-3191, 1999). For control, A375v cells were stably transfected with the empty expression vector (A375v/pCEP). Swiss nu/nu mice were s.c. injected with  $1 \times 10^6$  transfected A375v/sTie2 or A375v/pCEP tumor cells, respectively. Animals receiving compound I were treated for up to 38 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Various modes of treatment are described in Table 1. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 1

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

[0042] Tumors derived from A375v/pCEP control cells reached a size of approx. 250 mm<sup>2</sup> (mean area) within 24 days (Figure 1) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) or separate interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) delayed growth of tumors to a size of approx. 250 mm<sup>2</sup> to 31 days, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of interference with the VEGF/VEGF receptor system by means of the kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I + compound II, treatment group 4) delayed growth of the tumors to a size of approx. 250 mm<sup>2</sup> to 38 days. This result clearly demonstrates the superior effect of a combination of interference with the VEGF/VEGF receptor system and the Angiopoietin/Tie2 receptor system over separate modes of intervention.

#### Description of the figures

[0043] Fig. 1 shows the superior effect of combination of interference with VEGF/VEGF receptor system by means of an specific tyrosine kinase inhibitor and with the Angiopoietin/Tie2 receptor system by means of a soluble receptor domain on inhibition of tumor growth (treatment modes of groups 1-4 are given in Table 1). The abbreviations have the following meaning:

mock, con. = treatment group 1  
 mock+VEGF-A = treatment group 2  
 sTIE2-c113 = treatment group 3  
 sTIE2-c113+VEGF-A = treatment group 4

## Sequenzprotokoll

&lt;110&gt; Schering Aktiengesellschaft

&lt;120&gt; Combinations and compositions which interfere with VEGF/ VEGF and angiopoietin/ Tie receptor function and their use

&lt;130&gt; 51849AEPM1XX00-P

&lt;140&gt;

&lt;141&gt;

&lt;160&gt; 59

&lt;210&gt; 1

&lt;211&gt; 1835

&lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 1

```

ttttacagtt ttccttttct tcagagttta ttttgaattt tcatttttgg ataaccaage 60
agctcttttaa gaagaatgca cagaagagtc attctggcac ttttggatag tacataagat 120
tttctttttt ttttttaa atttttta atgcacattc agctcgcttg ctcaaaccag 180
actcccatcat tgggtgagca agatgagccc ataggattcc agagttaata cgtaaccgta 240
tatacaaaaca gccaaaaaac cataatggtg ccacagggat ggagcagga agggcatctc 300
taacgtgtcc tctagtctat cttcgctaaa cagaaccac gttacacatg ataactagag 360
agcacactgt gttgaaacga ggatgctgac cccaaatggc acttggcagc atgcagttta 420
aagcaaaaga gacatccttt aataactgta taaaatccag gcagttccat taaaggggtt 480
aagaaaacca acaacaacaa aaagcgaggg actgtctgtt gtcactgtca aaaaggcact 540
tggagtta atggaccagga ttggaggact cttagctgat acagatttca gtacgatttc 600
attaaaaggc ttggatgtta agagaggaca ctcagcgggt cctgaaggga gacgctgaga 660
tggaccgctg agaagcggaa cagatgaaca caaaggaaatc aaatctttac aaccaaattg 720
catttaagcg acaacaaaaa aaggcaaac ccaaaacgca acctaacaa agcaaaatct 780
aagcaaaatc agacaacgaa gcagcgatgc atagctttcc tttgagagaa cgatacctt 840
gagacgctac gtgccaacct aagttctcaa cgacagcttc acagtaggat tattgtgata 900
aaaatgactc aagcgatgca aaaagtttca tctgttccca gaatccgagg gagaactgag 960
gtgatcgtaa gagcatagcg acatcacgtg cggtttctta atgtccctgg tggcggatac 1020
gccgagtcct cgggaaggaca tctggacacc actttcagcc acctccttgc aggggcgaca 1080
tccgccaaag tcatccttta ttccgagtaa taactttaat tcttttctaa catttacacg 1140
gcaaacagga atgcagtaaa cgtccacgtc cgtcccacgg ctgggctgcc gttccgtttc 1200
ctccacgaac ggttacgcgc ttccatgaga aaggatattt ggcaatttta tattccacag 1260
tcaggtgggt ctgcgatagc tcatttaatg ttaaaccgca tcaggggcct ctctccctcg 1320
ttctgccagg ggttttctt gtcttctctc tggcgagctc gtgggcagat cttctctggt 1380
gggggctggc tgcgtgctcc gagggggcat ccgcagtcct tctggctcgtc tctctctgca 1440
ggctgggcag ctggccacca cttctccgac tccacccctc caacaagcat cgcagggcac 1500
tgtcctcggg ggtacagacc gtggtcccac attcgtacc actctgttcc acgtcatcca 1560
ggtacacgag ctgcgtgtag gccgtgctgt ctgggctcgt aggtcttttc tgctgggtgct 1620
cttggacggg cgggtagttc tgcgtcagag acaaagcatc tcccttccc ttccgggctg 1680
attttggttc attcatatct acgccagagt ccaaactggc atcattactt ccgttccttc 1740
cagctctttg gagaatcaat gtatgaatgt ctaacctgac cgttggacct gccatccaag 1800
gagacgaacc acgcccgggg gtgcggaagc ggcct

```

&lt;210&gt; 2

&lt;211&gt; 581

&lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 2

```

gttctagatt gttttattca gtaattagct ctttaagacc ctggggcctg tgctaccag 60
acactaaca cagtctctat ccagttgctg gttctgggtg acgtgatctc cccatcatga 120

```

tcaacttact tccgtgtggcc cattagggaa gtggtgacct cgggagctat ttgcctgttg 180  
 agtgcacaca cctggaaaaca tactgtctctc attttttcat ccacatcagt gagaaatgag 240  
 tggcccgtta gcaagatata actatgcaat catgcaacaa agctgcctaa taacatttca 300  
 tttattacag gactaaaaagt tcatttattgt ttgtaaagga tgaattcata acctctgcag 360  
 agttatagtt catacacagt tgatttccat ttataaaggc agaaagtcct tgttttctct 420  
 aaatgtcaag ctttgactga aaactcccg ttttccagtc actggagtgt gtgcgtatga 480  
 aagaaaatct ttagcaatta gatgggagag aagggaata gtacttgaaa ttagggccct 540  
 cacctcccca tgacatcctc catgagcctc ctgatgtagt g

<210> 3  
 <211> 516  
 <212> DNA  
 <213> Human

<400> 3

tagagatgtt ggttgatgac ccccgggatc tggagcagat gaatgaagag tctctggaag 60  
 tcagcccaga catgtgcac tacatcacag aggacatgct catgtcgagg aacctgaatg 120  
 gacactctgg gttgattgtg aaagaaattg ggtcttccac ctcgagctct tcagaaacag 180  
 ttgttaagct tctgtggccag agtactgatt ctcttccaca gactatatgt cggaaaccaa 240  
 agacctccac tgatcgacac agcttgagcc tcgatgacat cagactttac cagaaagact 300  
 tccctgcgcac tgcaggtctg tgtcaggaca ctgctcagag ttacacctt ggatgtggcc 360  
 atgaactgga tgaggaaggc ctctattgca acagttgctt ggcccagcag tgcatcaaca 420  
 tccaagatgc ttttccagtc aaaagaacca gcaataactt ttctctggat ctcaactcatg 480  
 atgaagtcc agagtttgtt gtgtaaagtc cgtctg

<210> 4  
 <211> 1099  
 <212> DNA  
 <213> Human

<400> 4

cccacaacac aggggcccctg aaacacgcc a gctctctc tgtggtcagc ttggcccagt 60  
 cctgtcact ggatcacagc ccattgtagg tggggcatgg tggggatcag ggcccctggc 120  
 ccacggggag gtagaagaag acctggtccg tgtaagggtc tgagaagggt ccctgggtcg 180  
 ggggtgcgtc ttggccttgc cgtgcccctca tcccccggt gaggcagcga cacagcaggt 240  
 gcaccaactc cagcaggtta agcaccagg agatgagtc aaccaccaac atgaagatga 300  
 tgaagatggt cttctccgtg gggcgagaga caaagcagtc cagcaggtag gggcaggggtg 360  
 ctgcgtggca cacaacacg ggctccatgg tcacgcccga caggcgcac ttggccataga 420  
 ggaagcctgc ctctagcaca ctcttgacaga gcacactggc gacatagggtg cccatcagtg 480  
 ctccgcggat gcgcaggcga ccactctctg ccaccgagat cttggccatc tgacgctcta 540  
 cggccgcag cgcgcgtcc acctgtgggt ccttgccgg cagtgcgcgc agtccccct 600  
 ccttctgcgc cagccgctct tctcgcgcag acaggtaaat gacatggccc aggtagacca 660  
 ggggtgggtg gctgacgaag aggaactgca gcacccagta gcggtgtgg gagatgggga 720  
 aggcctggtc atagcagacg ttggtgcagc ctggctgggc cgtgttacac tcgaaatctg 780  
 actgctcgtc accccacact gactcgcgg ccaggcccag gatgaggatg cggaagatga 840  
 agagcaccgt cagccagatc ttaccacca cggctcagtg ctccctggacc ttgtccagca 900  
 acttctccac gaagccccag tcacccatgg ctcccgggc tccgtcggca aggagacaga 960  
 gcacgtcagt gtgtcagcat ggcatccttc tcgttcgccc agcaacaagc ctgcagggag 1020  
 gtctgccacg cccgttctac cgcctgcctg ccgggcggcc caggtggagg tggggacgat 1080  
 ggccggagtg acgcccgcg

<210> 5  
 <211> 1015  
 <212> DNA  
 <213> Human

<400> 5

gaggataggg agcctgggggt caggagtgtg ggagacacag cgagactctg tctccaaaaa 60  
 aaaaagtgtc ttttgaaaat gttgaggttg aaatgatggg aaccaacatt ctttggattt 120  
 agtggggagc ataatagcaa acaccccctt ggttcgcaca tgtacaggaa tgggaccag 180  
 ttggggcaca gccatggact tccccccct ggaatgtgtg gtgcaaatgt gggccagggc 240  
 ccagacccaa gaggagaggg tggctccgag acaccccggg atgtcagcat ccccccagct 300  
 gccttctggc ggcacctccc ggggtgctgt ttgagtcagc aggcattggg tgagagcctg 360

EP 1 166 798 A1

gtatatgctg ggaacagggt gcaggggcca agcgttcttc cttcagcctt gacttggggc 420  
atgcaccccc tctcccccaa acacaaacaa gcacttcttc agtatgggtg caggacagg 480  
gtcccttcag tectctggtt atgactctca gtctacttg ggccctgcag cccagcctgt 540  
5 gttgtaacct ctgcgtcctc aagaccacac ctggaagatt cttcttccct ttgaaggaga 600  
atcatcattg ttgctttatc acttctaaga catltttgtac ggcacggaca agttaaacag 660  
aatgtgcttc cctccctggg gtctcaccag ctccacagag aatgccacag gggccgtgca 720  
ctgggcaggc ttctctgtag aaccccaggg gcttcggccc agaccacagc gtcttgccct 780  
gagcctagag cagggagtc cgaacttctg cattcacaga ccacctccac aattgttata 840  
accaaaggcc tctgtttctg ttatttctact taaatcaaca tgctattttg ttttctactca 900  
10 cttctgactt tagcctctgt ctgagccgtg tatccatgca gtcattgttca cgtgctagtt 960  
acgtttttct tcttacacat gaaaataaat gcataagtgt tagaagaaaa aaaaa

<210> 6  
<211> 2313  
<212> DNA  
15 <213> Human

<400> 6

ccagagcagg cctgggtggtg agcaggggagc gtgcaccgga cggcggggac gagcaaatgg 60  
gtctggccat ggagcacgga gggctcctacg ctccggcggg gggcagctct cggggctgct 120  
20 ggtattacct gcgctacttc tctctcttcg tctccctcat ccaattcctc atcatcctgg 180  
ggctcggtct cttcatggtc tatggcaacg tgcacgtgag cacagagtcc aacctgcagg 240  
gcaccgagcg ccgagccgag ggcctataca gtcagctcct agggctcacg gcctcccagt 300  
ccaacttgac caaggagctc aacttcacca cccgcgcca ggatgccatc atgcagatgt 360  
ggctgaatgc tcgcccgcgac ctggaccgca tcaatgccag cttccgcccag tgccaggggtg 420  
accgggtcat ctacacgaac aatcagaggt acatggctgc catcatcttg agtgagaagc 480  
25 aatgcagaga tcaattcaag gacatgaaca agagctgcga tgccctgtct ttcattgtga 540  
atcagaagggt gaagacgctg gaggtggaga tagccaagga gaagaccatt tgcactaagg 600  
ataaggaaaag cgtgctgtct aacaaacgcg tggcgaggga acagctggtt gaatgcgtga 660  
aaaccgggga gctgcagcac caagagcgcc actggccaag gagcaactgc aaaaggtgca 720  
agccctctgc ctgcccctgg acaaggacaa gtttgagatg gaccttcgta acctgtggag 780  
30 ggaactcatt atcccacgca gcctggacaa cctgggttac aacctctacc atcccctggg 840  
ctcggaattg gcctccatcc gcagagcctg cgaccacatg cccagcctca tgagctccaa 900  
gggtggaggag gctgcccggg ggcctccggg ggatatacga cgcgtggccc gcgagaactc 960  
agacctccaa cgccagaagc tggaaagccca gcagggcctg cggggcagtc agggaggcga 1020  
acagaagggtg gagaaggagg ctacggcccc ggaggccaag ctccaagctg aatgctccc 1080  
gcagagccag ctacgctggt aggagaaggc ggtgctgcgg aaggaaacgag acaacctggc 1140  
caaggagctg gaagagaaga agaggagggc ggagcagctc aggatggagc tggccatcag 1200  
35 aaactcagcc ctggacacct gcatcaagac caagtgcgag ccgatgatgc cagtgtcaag 1260  
gcccattggg cctgtcccca acccccagcc catcgacca gctagcctgg aggagtcaa 1320  
gagggaagtc ctggagtccc agaggcccc tgcaggcatc cctgtagccc catccagtgg 1380  
ctgaggaggc tccaggcctg aggaaccaag gatggcccga ctcggcggtt tgcggaggat 1440  
gcagggatat gctcacagcg cccgacacaa cccctctccc cgcgccccaa ccaccaggg 1500  
ccaccatcag acaactccct gcatgcaaac ccctagtacc ctctcacacc cgcacccgcg 1560  
40 cctcacgac cctcacccag agcacacggc cgcgagatg acgtcacgca agcaacggcg 1620  
ctgacgtcac atatcacctg ggtgatggcg tcacgtggcc atgtagacgt cacgaagaga 1680  
tatagcgatg gcgtcgtgca gatgcagcac gtcgcacaca gacatgggga acttggcatg 1740  
acgtcacacc gagatgcagc aacgacgtca cgggcatgt cgacgtcaca catattaatg 1800  
tcacacagac gcggcgatgg catcacacag acggtgatga tgtcacacac agacacagt 1860  
acaacacaca ccatgacaac gacacctata gatatggcac caacatcaca tgcacgcatg 1920  
45 ccctttcaca cacactttct acccaattct caacctagtgt cacttcccc cgaccctggc 1980  
acacgggcca aggtaccac aggtatccat cccctcccgc acagccctgg gcccagcac 2040  
ctccctcct ccagcttctt ggcctcccag ccacttcttc acccccagtg cctggaccgg 2100  
gaggtgagaa caggaagcca ttcacctccg ctcttgagc gtgagtgtt ccaggacccc 2160  
ctcggggccc tgagccgggg gtgaggggtca cctgtgtgct ggaggggagc cactccttct 2220  
50 cccccaactc ccagccctgc ctgtggcccg ttgaaatgtt ggtggcactt aataaatatt 2280  
agtaaatcct taaaaaaaa aaaaaaaaaa aaa

<210> 7  
<211> 389  
<212> DNA  
55 <213> Human

<400> 7

EP 1 166 798 A1

5  
gccccaaaaga tggccttcaaa agtaagaatg aaacatttga tccattcagc tttaggctat 60  
gccactggat tcatgtctag aaaagatagg ataatttctg taaagaaatg aagaccttgc 120  
tattctaaaaa tcagatcctt acagatccag atttcaggaa acaatacat aggggactaa 180  
ctttccttgt tcagattagt ttttctcctt tgcacccagc tatataatat gaggaagtat 240  
tgacttttta aaagtgtttt agttttccat ttctttgata tgaaaagtaa tatttcggga 300  
gaacctgag ctattaataa tctatgtggc tagtgcgat atattggct gaatttggtc 360  
tccttttgtg gtgtccagt ggtaacatc

10  
<210> 8  
<211> 157  
<212> DNA  
<213> Human

15  
<400> 8  
tgctttaaac agctgtgtca aaaactgaca tcagagagta aattgaattt ggttttgtag 60  
gaagcaggaa gcaagccac tcaaactgta aatttggcat gagggatcca gtaactttct 120  
cctcaatctg tgaactatat gtgagtttga tattttg

20  
<210> 9  
<211> 561  
<212> DNA  
<213> Human

25  
<400> 9  
aatagtcaaa acataaacia aagctaatta actggcactg ttgtcacctg agactaagtg 60  
gatgttgttg gctgacatac aggtcagacc agcagagaaa gaattctgaa tcccccttgc 120  
tgaactgaac tattctgtta catatgtgtg acaaactctgt gtgttatttc ttttctacct 180  
accatattta aatttatgag tatcaaccga ggacatagtc aaaccttcga tgatgaacat 240  
tcctgatttt ttgcctgatt aatctctgtt gagctctact tgtggtcatt caagatttta 300  
tgatgttgaa aggaaaagtg aatatgacct ttaaaaattg tattttgggt gatgatagtc 360  
tcaccactat aaaactgtca attattgcct aatgttaaag atatccatca ttgtgattaa 420  
ttaaacctat aatgagtatt cttaattggag aattcttaat ggatggatta tccccgtatc 480  
ttttctttaa aatttctctg cacacacagg acttctcatt ttccaataaa tgggtgtact 540  
ctgccccaat ttctaggaaa a

30  
<210> 10  
<211> 1508  
<212> DNA  
<213> Human

35  
<400> 10  
cacaacacag agagactcca cgtgtgcct gagcaccgcc agcctcctag gctccagcac 60  
tcgcaggtcc attcttctgc acgagcctct ctgtccagat ccataagcac ggtcagctca 120  
gggtcgcgga gcagtacgag gacaagtacc agcagcagct cctctgaaca gagactgcta 180  
ggatcatcct tctcctccgg gcctgttgcct gatggcataa tccgggtgca acccaaatct 240  
gagctcaagc caggtgagct taagccactg agcaaggaa atttgggect gcacgcctac 300  
aggtgtgagg actgtggcaa gtgcaaatgt aaggagtga cctacccaag gcctctgcca 360  
tcagactgga tctgcgacaa gcagtgcctt tgctcggccc agaactgat tgactatggg 420  
acttgtgtat gctgtgtgaa aggtctcttc tatcactgtt ctaatgatga tgaggacaac 480  
tggtgtcatgt acccatgttc ttgcagccag tctcactgtt gtacacgatg gtcagccatg 540  
gggtgtcatgt cctctttttt gccttgttta tgggtgtacc ttccagccaa ggggtgcctt 600  
aaattgtgcc aggggtgtta tgaccgggtt aacaggcctg gttgccgctg taaaaactca 660  
aacacagttt gctgcaaagt tcccactgtc ccccctagga actttgaaaa accaactatg 720  
catcattaat caggaatatt acagtaatga ggattttttc tttctttttt taatacacat 780  
atgcaaccaa ctaaaacagtt ataactcttg cactgttaat agaaagtgtg gatagtcttt 840  
gctgtttgct gtgaaatgct ttttgtccat gtgcggtttt aactgatatg cttgttagaa 900  
ctcagctaat ggagctcaaa gtatgagata cagaacttgg tgaccatgt attgcataag 960  
ctaaagcaac acagacactc ctaggcaaac tttttgttg tgaaatgtac ttgcaaaact 1020  
tgtaaatag cagatgactt ttttccattg ttttctccag agagaatgtg ctatatTTTT 1080  
gtatatacaa taatatTTTgc aactgtgaaa acaagtgtt gccatactac atggcacaga 1140  
cacaaaatat tatactaata tgtgtgacat tcggaagaat gtgaatcaat cagtatgttt 1200  
ttagattgta ttttgctta cagaaagcct ttattgttaag actctgattt ccttttggac 1260  
ttcatgtata ttgtacagtt acagtaaaat tcaaccttta ttttctaatt ttttcaacat 1320



EP 1 166 798 A1

attgtttagt gtaaagaata tttatttgaa gttttattat tttataaaaa agaattattta 1380  
 ttttaagagg catcttaca attttgcccc ttttatgagg atgtgatagt tgctgcaa 1440  
 gaggggttac agatgcata gtccaatata aaatagaaaa tatattaacg tttgaaatta 1500  
 aaaaaaaaa

<210> 11  
 <211> 389  
 <212> DNA  
 <213> Human

<400> 11

gggcagggtga tcagggcaca catttcccg ccatgagac agtagcattc ccggcaccca 60  
 tcgtgccagc tctcctcatt tttatgatga tgaccatcca cggtgagaca agtgcccagc 120  
 aggatgggtg gccagctga agcacaggcc gctctgca tgcagataag acagccgtga 180  
 ctgtcctgct ggaaacccaa ggggcagatc ttactgcatg agagctctgg acatttctta 240  
 cagcgacaga gttcacagcc gtgcttattc ttcagcaatc caagtggaca atacttgta 300  
 cagattatgg gtctgcactt cttgggcctt gggcggcact cacagatctc acagttttgg 360  
 acctcgcccg cgaccacgct ggggtaccga

<210> 12  
 <211> 981  
 <212> DNA  
 <213> Human

<400> 12

tttttttttt ttggattgca aaaatttatt aaaattggag aactgtttt aatcttcttg 60  
 tgccatgaga ctccatcagg cagtctacaa agaccactgg gaggtgagg atcacttgag 120  
 ccagaaagtt tgaggctgta gtaagcttca aaggccactg cactctagct tgggtgaggc 180  
 aagacctttt caagcagtaa gctgcatgct tgcttgtgt ggtcattaaa aaccctagtt 240  
 taggataaca acatattaat cagggcacaaa tacaatgtg tgatgcttg tagtagagta 300  
 acctcagaat caaatggaa cggttttaca gtgatcat tatatttcat ttggcagaat 360  
 cattacatca ttggttacac tgaaaatcat cacatgtacc aaaagctgac tcacctagtt 420  
 taggataaca ggtctgctg tttgaagatg aaaaataata cccattttaa atttgcccta 480  
 ctcaatttcc ttctcagta cattttaact tttaaacagc taatcactcc catctacaga 540  
 ttaagggtga tatgccacca aaacctttt ccacctttaa aatttcttc aaagttaa 600  
 ctaatgcctg catttcttca atcatgaatt ctgagctct tgcttctt aaacttgctc 660  
 cacacagtgt agtcaagccg actctccata cccaagcaag tcatccatgg ataaaaacgt 720  
 taccaggagc agaaccatta agctgggtcca ggcaagttgg actccaccat ttcaacttcc 780  
 agctttctgt ctaatgcctg tgtgccaatg gcttgagtta ggcttgctct ttaggacttc 840  
 agtagctatt ctcatcctc cttggggaca caactgtcca taagtgcta tccagagcca 900  
 cactgcatct gcacccagca ccatacctca caggagtcga ctcccacgag ccgctgtat 960  
 ataagagttc ttttgatgac g

<210> 13  
 <211> 401  
 <212> DNA  
 <213> Human

<400> 13

ataactacag cttcagcaga caactaaaga gactgcatta aggtgatttc tctggctata 60  
 aagagagccc ggccgcagag catgtgactg ctgggacctc tgggataggc aacactgccc 120  
 tctctcccc agagcgaccc cccgggcagg tcggggccca aggaatgacc cagcaactgc 180  
 tccctaccca gcaactctc tttactgcca cctgcaatta tgctgtgaag atgactgggt 240  
 gtgggtcatca cgattcagag aaatcaagat ctatgaccat tttaggcaaa gagagaaact 300  
 tggagaattg ctgaggacta ctgaaccttg ttttgctttt ttaaaaaata ctaaactctc 360  
 acttcagcat atttagttgt cattaaaatt aagctgatat t

<210> 14  
 <211> 1002  
 <212> DNA  
 <213> Human

<400> 14

EP 1 166 798 A1

5  
10  
15

gacaatataa	aaagtggaaa	caagcataaa	ttgcagacat	aaaataatct	tctggtagaa	60
acagttgtgg	agaacagggt	gagtagagca	acaacaacaa	aagcttatgc	agtcaccttc	120
tttgaataatg	tttaatacaa	gtcctattct	ctttgtccag	ctgggtttag	ctagaggtag	180
ccaattactt	ctcttaaggt	ccatggcatt	cgccaggatt	ctataaaagc	caagttaact	240
gaagtaaata	tctggggccc	atcgcacccc	cactaagtac	tttgtcacca	tgtgtatct	300
taaaagtcac	ttttcactgt	ttgactcaga	atttgggact	tcagagtcaa	acttcattgc	360
ttactccaaa	cccagtttaa	ttcccacttt	ttttaagtag	gcttagcttt	gagtgtttt	420
tggctataac	cgaatgtaa	atccaccttc	aaacaacaaa	gtttgacaag	actgaaatgt	480
tactgaaaac	aatggtgcca	tatgtcccaa	agacatttcc	ccaagataac	tgccaaagag	540
tttttgagga	ggacaatgat	catttattat	gtaggagcct	tgatatctct	gcaaaataga	600
attaatacac	ctcaaatgga	gtagtaacca	agcttttctg	cccagggaag	aacaaacatc	660
actacgaaca	tgagagtaca	agaggaaact	ttcataatgc	attttttcat	tcatacatct	720
attcaataaa	cattagccaa	gctaagtgtc	caagccactg	tgccaggtag	taacaatata	780
acaacaataa	aagacacagt	ccttcctctc	aaggtgttca	gtctagttag	gaagatgatt	840
attcattaaa	atttttggtg	catcagaatc	atgaggagct	tgtcaaaaat	gtaaattcct	900
gacctgttct	tcagatattc	tggttagggt	aggagtggga	acccaaaatc	aattctttta	960
acaaacacta	aaggtgattc	taacacaggc	ggtgtgagga	cc		

<210> 15  
<211> 280  
<212> DNA  
<213> Human

<400> 15

25

cgaggtgggc	cacccgtgtc	tggctctgaga	tttttaaatg	aggattacat	tatcctatct	60
ataatattcc	tattctaata	tattgtattc	ttacaattaa	atgtatcaaa	taattcttaa	120
aaacattatt	agaacaaaac	tgcctaatac	cttataagac	taaaaaaatc	accaagatga	180
aactgtatta	tgactctcaa	tatttaaaaca	tttaaaaaaa	tgtagtggt	tgtaagcac	240
caatcttaac	tatttcacct	gcccgggcgg	ccgctcgagg			

<210> 16  
<211> 2041  
<212> DNA  
<213> Human

<400> 16

35  
40  
45  
50  
55

ccccccgcag	aactcccccc	tggaatagga	tttttaaaac	ccttgacaat	tagaaatcct	60
atagagggtta	gcatttttta	ggtaaaaata	tgggtgcccc	tacagggatc	atgcaacttc	120
cttaaaacca	attcagcaca	tatgtataaa	gaaccctttt	taaaaacatt	tgtacttgaa	180
atacagacac	agtgtgctg	aagacactaa	acaaaaactg	aaaagtacta	taccttgata	240
aatttttgta	ttgcttctt	tagagacttt	ataatctcta	gttgattttc	aaggacttga	300
atttaataat	gggtaatta	cacaagacgt	aaaggatttt	ttaaaaacaa	gtattttttt	360
ttacctctag	catcaattct	tttataaaga	atgctaaata	aattacattt	tttgttcagt	420
aaaactgaag	atagaccatt	taaatgcttc	taccaaattt	aacgcagctt	aattagggac	480
cagggtacata	ttttcttctg	aacatttttg	gtcaagcatg	tctaaccata	aaagcaaatg	540
gaatttttaag	aggtagattt	tttttccatg	atgcattttg	tttaataaat	tgtcaagaaa	600
ataaaaacaa	gcactgagtg	tgttctcttg	aagtataagg	gtctaataag	aaataaaaga	660
tagataatttg	ttatagctg	acattttaac	agtcatagta	ttagacgttt	cgtgaccagt	720
gcatttttga	ctctctcagg	atcaaaaatac	gagctctgcca	actgtattaa	atcctcctcc	780
acccctcca	ccagttggtc	cacagcttcc	tgggtgggtcg	ttgtcatcaa	atccattggg	840
ccgaaatgaa	catgaagcag	atgcagcttg	gagggcccg	gctcgagcat	tcaactcttg	900
ttcctgtaaa	tatagtttat	tgtcttttgt	tatagcatcc	ataagttctt	tctgtagagg	960
tgggtctcca	tttatccaga	gtccactggt	tgggttatta	ccacttaaac	cattagtact	1020
atgctgtttt	ttatacaaaa	gcacataagc	tgtgtccttt	ggaaacctgc	tcgtaatttt	1080
ctggactgac	tgaaatgaag	taaatgtcac	tctactgtca	ttaaataaaa	acccattctt	1140
ttgacatttc	cttattttcc	aaatcctggt	caaaaactgc	actgggacta	tctctcccta	1200
gtaaatgact	ctgggaggat	gctaagtcca	gagcctcaga	ctggtgtgac	atctgatatg	1260
aagagctctgt	acttgtgata	tttctggcat	aagaatagta	atgccactt	tcagaggata	1320
taccagagtg	aaccacaacg	gaacttaata	gatagggcac	caattttgtg	caggaagctt	1380
catcagctccc	tgaaggcttt	aatttttttag	caaggttctc	actaagatca	gtgaagtcaa	1440
catctacaga	ccaactttct	gacaatgaag	agaaagaagt	aattcttcta	actggcaact	1500
ccaaaaccag	tggccagtga	tacattgtct	aaaattttcc	ttctcacatg	atacttctga	1560
tcatatgaaa	atctcaggag	agtaagaata	aggatttcag	gttcctccgt	gatttgcata	1620

EP 1 166 798 A1

gttttctcag cattttgcag agaggcacag ttttcacaat aatattgggt atcaccagta 1680  
 agaattctctg gagcccaaaa aataatttag taagtcagtt actgaagggt tggtttcacc 1740  
 tcccgggtttc tgaggtacat ctttattaac aagaatcttg ttagattcgt tagggacaga 1800  
 5 agtgttttca gaacagtaaa actcattagg aggactgctt atgggttttt cattcacaag 1860  
 tgagtcacag atgaaggcag ctgttggttg attataaact actggctctt ctgaaggacc 1920  
 gggtagacag gcttgcatga gaccaccatc ttgtatactg ggtgatgatg ctggatcttg 1980  
 gacagacatg ttttccaaag aagaggaagc acaaaacgca agcgaagat ctgtaaaggc 2040  
 t

<210> 17  
 <211> 235  
 <212> DNA  
 <213> Human

<400> 17

15 cgccccgggc aggtgtcagg ggttccaaac cagcctgggg aaacacagcg tagacccttc 60  
 acctctacaa ataaaaaatt aaaaaattag ccaggtgtgg cagcgaacaa ctgtagtctc 120  
 agatactcag gagactgagc tggaaaggat cacttgagcc caagaagttc aaggttacag 180  
 tgggccacga tcatgtcatt acactccagc ttgggtgaca aaatgagact gtcta

<210> 18  
 <211> 2732  
 <212> DNA  
 <213> Human

<400> 18

25 gtgtggagtt tcagctgcta ttgactataa gagctatgga acagaaaaag cttgctggct 60  
 tcatgttgat aactacttta tatggagctt cattggacct gttaccttca ttattctgct 120  
 aaatattatc ttcttggtga tcacattgtg caaaatgggt aagcattcaa acactttgaa 180  
 accagattct agcaggttgg aaaacattaa gtcttgggtg cttggcgctt tgcctcttct 240  
 gtgtcttctt ggcctcacct ggtccttttg gttgcttttt attaatgagg agactattgt 300  
 30 gatggcatat ctcttcacta tatttaatgc tttccaggga gtgttcattt tcatctttca 360  
 ctgtgctctc caaaagaaag tacgaaaaga atatggcaag tgcttcagac actcatactg 420  
 ctgtggaggg ctcaccaactg agagtcccca cagttcagtg aaggcatcaa ccaccagaac 480  
 cagtgtctgc tattctctctg gcacacagag tcgtataaga agaattgtga atgatactgt 540  
 gagaaaaaaa tcagaatctt ctcttatctc aggtgacatc aatagcactt caacacttaa 600  
 tcaaggtggc ataaatctta atatattatt acaggactga catcacatgg tctgagagcc 660  
 catcttcaag atttatatca tttagaggac attcactgaa caatgccagg gatacaagt 720  
 35 ccatggatac tctaccgcta aatggtaatt ttaacaacag ctactcgtg cacaagggtg 780  
 actataatga cagcgtgcaa gttgtgact gtggactaag tctgaatgat actgcttttg 840  
 agaaaatgat catttcagaa ttagtgcaca acaacttacg gggcagcagc aagactcaca 900  
 acctcgagct cagctacca gtcacacctg tgattggagg tagcagcagt gaagatgatg 960  
 ctatttgggc agatgcttca tctttaatgc acagcgacaa cccagggtg gagctccatc 1020  
 40 acaagaact cgaggacca cttattcctc agcggactca ctccctctg taccaacccc 1080  
 agaagaaagt gaagtccgag ggaactgaca gctatgtctc ccaactgaca gcagaggctg 1140  
 aagatcacct acagtccccc aacagagact ctctttatag aagcatgccc aatcttagag 1200  
 actctcccta tccggagagc agccttgaca tggaaagaaga cctctctccc tccaggagga 1260  
 gtgagaatga ggacatttac tataaaagca tgccaaatct tggagctggc catcagcttc 1320  
 agatgtgcta ccagatcagc aggggcaata gtgatgggtt tataatcccc attacaaaag 1380  
 aaggggtgat tccagaagga gatgttagag aaggacaaat gcagctgggt acaagtcttt 1440  
 45 aatcatacag ctaagggaatt ccaagggcca catgcgagta ttaataaata aagacacat 1500  
 tggcctgacg cagctccctc aaactctgct tgaagagatg actcttgacc tgtggttctc 1560  
 tgggtgtaaaa aagatgactg aaccttgagc ttctgtgaat ttttataaaa catacaaaaa 1620  
 ctttgtatat acacagagta tactaaagtg aattatttgt taaaaagaaa agagatgcca 1680  
 gccaggtatt ttaagattct gctgctgttt agagaaattg tgaaacaagc aaaacaaaac 1740  
 tttccagcca ttttactgca gcagctctgt aactaaattt gtaaataatg ctgcaccatt 1800  
 50 tttgtaggcc tgcattgtat tatatacaag acgtaggctt taaaatcctg tgggacaaat 1860  
 ttactgtacc ttactattcc tgacaagact tggaaaagca ggagagatat tctgcatcag 1920  
 tttgcagttc actgcaaatc ttttaactta aggcgaagat tgaaaacatg cttaaccact 1980  
 agcaatcaag ccacaggcct tatttcatat gtttctcaa ctgtacaatg aactattctc 2040  
 atgaaaaatg gctaaagaaa ttatatattt ttctatttgt agggtaaaat aaatacattt 2100  
 gtgtcccaact gaaatataat tgtcattaaa ataattttta agagtgaaga aaatattgtg 2160  
 55 aaaagctctt ggttgacat gttatgaaat gtttttctt acactttgtc atggtaagtt 2220  
 ctactcattt tcaactcttt tccactgtat acagtgttct gctttgacaa agtttagctt 2280

EP 1 166 798 A1

tattactttac atttaaattt cttattgcca aaagaacgtg ttttatgggg agaaacaaac 2340  
tcttttgaagc cagtttatgtc atgccttgca caaaagtgat gaaatctaga aaagattgtg 2400  
tgtaacccctt gtttattctt gaacagaggg caaagagggc actgggcact tctcacaac 2460  
tttctagtga acaaaagggt cctattcttt tttaaaaaa taaaataaaa cataaatatt 2520  
actcttccat attccttctg cctattttta gtaattaatt tattttatga taaagtctta 2580  
atgaaatgta aattgtttca gcaaaattct gctttttttt catccctttg tgtaaacctg 2640  
ttaataatga gcccatcact aatatccagt gtaaagttta acacggtttg acagtaaata 2700  
aatgtgaatt ttttcaagtt aaaaaaaaaa aa

<210> 19  
<211> 276  
<212> DNA  
<213> Human

<400> 19

ctccctaataat gattttaaaa taaattggat aaacatatga tataaagtgg gtacttttaga 60  
aaccgccttt gcatattttt tatgtacaaa tctttgtata caattccgat gttccttata 120  
tattccctat atagcaaac aaaaccagga cctcccaact gcatgcctca agtccctgtg 180  
gagcactctg gcaactggat ggcctcactt gctttctgac aaaatagctg gaaaggagga 240  
gggaccaatt aaatacctcg gccgcgacca cgctgg

<210> 20  
<211> 2361  
<212> DNA  
<213> Human

<400> 20

attgtaccag ccttgatgaa cgtgggccct gcttcgcttt tgagggccat aagctcattg 60  
cccactggtt tagaggctac cttatcattg tctcccgatg ccggaaggtt tctcccaagt 120  
cagagtttac cagcagggat tcacagagct ccgacaagca gattctaac atctatgacc 180  
tgtgcaacaa gttcatagcc tatagcaccg tctttgagga tgtagtggtt gtgcttgctg 240  
agtggggctc cctgtacgtg ctgacgcggg atgggcgggt ccacgcactg caggagaagg 300  
acacacagac caaactggag atgctgttta agaagaacct atttgagatg gcgattaacc 360  
ttgccaagag ccagcatctg gacagtgtat ggctggccca gattttcatg cagtatggag 420  
accatctcta cagcaagggt aaccacgatg gggctgtcca gcaatatac cgaaccattg 480  
gaaagtggga gccatcctac gtgatccgca agtttctgga tgcccagcgc attcacaacc 540  
tgactgccta cctgcagacc ctgcaccgac aatccctggc caatgccgac cataccacc 600  
tgctcctcaa ctgctatacc aagctcaagg acagctcgaa gctggaggag ttcatcaaga 660  
aaaagagtga gagtgaagtc cactttgatg tggagacagc catcaaggte ctccggcagg 720  
ctggctacta ctcccatgcc ctgtatctgg cggagaacca tgcatcatcat gagggtgacc 780  
tgaagatcca gctagaagac attaagaatt atcaggaagc ccttcgatac atcggcaagc 840  
tgcttttga gcaaggcagag agcaacatga agcgctacgg caagatcctc atgcaccaca 900  
taccagagca gacaactcag ttgctgaagg gactttgtac tgattatcgg cccagcctcg 960  
aaggcccgag cgatagggag gccccaggct gcagggccaa ctctgaggag ttcatcccca 1020  
tctttgcaa taaccgcgca gagctgaaag ccttcttaga gcacatgagt gaagtgcagc 1080  
cagactcacc ccaggggatc tacgacacac tccttgagct gcgactgcag aactgggccc 1140  
acgagaagga tccacaggte aaagagaagc ttcacgcaga ggccatttcc ctgctgaaga 1200  
gtggtcgctt ctgacagctt ttgacaagg ccctgtcct gtgccagatg cagcacttcc 1260  
aggatggtgt cctttacctt tatgagcagg ggaagctgtt ccagcagatc atgcactacc 1320  
acatgcagca cgagcagtag cggcaggtca tcagcgtgtg tgagcgccat ggggagcagg 1380  
acccctcctt gtgggagcag gccctcagct acttcgctcg caaggaggag gactgcaagg 1440  
agtatgtggc agctgtcctc aagcatatcg agaacaagaa cctcatgcca cctcttctag 1500  
tggtgcagac cctggcccac aactccacag ccacactctc cgtcatcagg gactacctgg 1560  
tccaaaaact acagaacacag agccagcaga ttgcacagga tgagctgcgg gtgcggcggg 1620  
accgagagga gaccaccggt atccgcccag agatccaaga gctcaaggcc agtcctaaga 1680  
ttttccaaaa gaccaagtgc agcatctgta acagtgcctt ggagttgccc tcagtccact 1740  
tcctgtgtgg ccactccttc caccaacact gctttgagag ttactcgaa agtgatgctg 1800  
actgccccac ctgectcctt gaaaaccgga aggtcatgga tatgatccgg gcccggaac 1860  
agaacagaga tctccatgat caattccagc atcagctcaa gtgctccaat gacagctttt 1920  
ctgtgatgtc tgactacttt ggcagaggtg ttttcaacaa attgactctg ctgaccgacc 1980  
ctcccacagc cagactgacc tccagcctgg aggctgggct gcaacgcgac ctactcatgc 2040  
actccaggag gggcacttaa gcagcctgga ggaagatgtg ggcaacagtg gaggaccaag 2100  
agaacagaca caatgggacc tgggcgggct ttacacagaa ggctggctga catgcccagg 2160  
gctccactct catctaattg cacagccctc acaagactaa agcggaaact tttcttttcc 2220

EP 1 166 798 A1

ctggccttcc ttaattttaaa gtcaagcttg gcaatccctt cctctttaac taggcaggtg 2280  
ttagaatcat ttccagatta atggggggga aggggaacct caggcaaac tctgaagtt 2340  
ttggaaaaaa aagctggttt c

<210> 21  
<211> 179  
<212> DNA  
<213> Human

<400> 21

agggtgtaga tgctcttgaa aaagaaactg catctaagct gtcagaaatg gattctttta 60  
acaatcaact aaaggaactg agagaaacct acaacacaca gcagttagcc cttgaacagc 120  
tttataagat caacgtgaca agttgaagga aattgaaagg aaaaaattag aactaatgc

<210> 22  
<211> 905  
<212> DNA  
<213> Human

<400> 22

tttttttttt ttctttaacc gtgtggtctt tatttcagtg ccagtgttac agatacaaca 60  
caaatgttcc agttagaagg aattcaaacg gaatgccaa gtcacagcca ggctcaagaa 120  
ataaaaaggg aggttttgag taatagataa gatgactcca atactcactc ttccctaaagg 180  
caaaggctact ttgtatacag agtctgatct ttgaaactgg tgaactcctc ttccaccat 240  
taccatagtt caaacaggca agttatgggc ttaggagcac tttaaaattt gtgggtggaa 300  
tagggctcatt aataactatg aatatactct ttagaaggtg accattttgc actttaagg 360  
gaatcaattt tgaaaatcat ggagactatt catgactaca gctaaagaat ggcgagaaag 420  
gggagctgga agagccttgg aagtctctat tacaataga gcaccatata cttcatgcca 480  
aatctcaaca aaagctcttt ttaactccat ctgtccagtg tttacaaata aactcgcaag 540  
gtctgaccag ttcttggtta caaacatata tgtgtgtgtc tgtgtgtata cagcaatgca 600  
cagaaaaggc taccaggagc ctaatgcctc tttcaaacat tgggggaacc agtagaaaaa 660  
ggcagggtct cctaagtcc attattacat ttccattccg aatgccagat gttaaaagt 720  
cctgaagatg gtaaccagc tagtgaggaa taaatacccc accttgccca gtccacagag 780  
aaacaacagt agaaagaagg ggaactctt tgctgcagag acaaaagtga tggtttttcg 840  
ccatggattg cagtctctc ctccagacca gctgcttatt tctcagggg cccagggaa 900  
gttga

<210> 23  
<211> 2134  
<212> DNA  
<213> Human

<400> 23

ggctctcttct ttcttttttt tttttccaaa agtgttcttt tatttctagt aacatatatt 60  
gtataaatat tctattttat atgcacttcc acaaaagcga tataatttaa aagttttttt 120  
cattagaagt aaatgtataa aaataaatat gttattatag gcatttatta ctaactatag 180  
tccttcttgg aaggaacacc caaaccaata cttataaagt acatgtaatt tatagtaaca 240  
tattttacta tatacatatg gaaaaaatca tattctcaca gaagagctga acagacattc 300  
accaggatac gactgttggg ccagctgctg gagatggacc tgctaccctc cagcagcctc 360  
cccaccacaa gacaagtgat ctcaatgtcc ccaaacctgt gggaccctgt tctacacacc 420  
tcatttttgt tccggcggtt catcctcctt gtgtgattgt actgattttc atgagacaca 480  
agttacttct ttacatccat attcccaag cagggttaca tggtaggaaa gaaaggaggt 540  
tggagggtact aagctcattg tgtctcctct agcttttacc agcatctaatt gcttcactgc 600  
tttttttcca ttgtagactt taatgcactt gaataaatat atggagttgt ttttctctca 660  
aaatgaatta cacaaataaa gactgagatg gtccaaaaaa ggaaagagga agccatttgc 720  
gttatttcac gttgctgagc ctttctctca tgttgaacaa tctgaagttt taattctcgg 780  
tagaaaatat gtataaacat tctctgaaac catagcagcc ataaacagtg ctggtcaag 840  
atcctatttg tactccttcc tcccctcatt gttagtggg taaagtaaaa cagggtcttag 900  
taaaatctca cttttctcct acttttcatt tcccaacccc catgatacta agtatttgat 960  
aagtaccagg aaacaggggt tgtaaatagt ctaacttttt ttgacaattg ctttgttttt 1020  
tctaactttg taatagatgt aacaaaagaa ataataataa taatgcccg ggctttatta 1080  
tgctatatca ctgctcagag gttataaatc ctaactaact atcctatcaa atttgcaact 1140  
ggcagtttac tctgatgatt caactccttt tctatctacc cccataatcc caccttactg 1200

5 atacacctca ctgggtactg gcaagatacg ctggatccct ccagccttct tgctttccct 1260  
 gcaccagccc ttccctcactt tgccttgccc tcaaagctaa caccacttaa accacttaac 1320  
 tgcattctgc cattgtgcaa aagtctatga aatgtttagg tttctttaaa ggatcacagc 1380  
 tctcatgaga taacacccct ccatcatggg acagacactt caagcttctt tttttgtaac 1440  
 ccttcccaca ggtcttagaa catgatgacc actccccag ctgccactgg gggcagggat 1500  
 ggtctgcaca aggtctgggt ctggctggct tcaacttctt tgcacactcg gaagcaggct 1560  
 gtccattaat gtctcgcat tctaccagtc ttctctgcca acccaattca catgacttag 1620  
 aacattcgcc ccactcttca atgacccatg ctgaaaaagt ggggatagca ttgaaagatt 1680  
 ccttcttctt ctttacgaag taggtgtatt taattttagg tcgaagggca ttgccacacag 1740  
 10 taagaacctg gatggtcaag ggtcttttga gagggtctaa gctgcgaatt ctttccaatg 1800  
 ccgcagagga gccgctgtac ctcaagacaa cacttttcta cataatgtct tgctctaagg 1860  
 tggacaaagt gtagtcacca ttaagaatat atgtgccatc agcagctttg atggcaagaa 1920  
 agctgccatt gttcctggat ccctctggtt tccgctgttt cacttcgatg ttggtggctc 1980  
 cagttggaat tgtgatgata tcatgatatc caggttttgc actagtaact gatcctgata 2040  
 tttttttaca agtagatcca ttccccgc aaacaccaca tttatcaaac ttctttttgg 2100  
 15 agtctatgat gcgatcaca ccagctttta caca

<210> 24  
 <211> 1626  
 <212> DNA  
 <213> Human

<400> 24

20 ggacaatttc tagaatctat agtagtatca ggatatattt tgctttaaaa tatattttgg 60  
 ttattttgaa tacagacatt ggctccaaat ttcatcttt gcacaatagt atgacttttc 120  
 actagaactt ctcaacattt gggaactttg caaatatgag catcatatgt gtttaaggctg 180  
 25 tatcatttaa tgctatgaga tacattgttt tctccctatg ccaaacaggt gaacaaacgt 240  
 agttgttttt tactgatact aaatgttggt taccctgtgat tttatagtat gcacatgtca 300  
 gaaaaaggca agacaaatgg cctctgttac tgaatacttc ggcaaaactta ttgggtcttc 360  
 attttctgac agacaggatt tgactcaata ttgttagagc ttgcgtagaa tggattacat 420  
 ggtagtgtat cactggtaga aatggttttt agttattgac tcagaattca tctcaggatg 480  
 aatcttttat gtctttttat tgaagcata tctgaattta ctttataaag atggtttttag 540  
 30 aaagctttgt ctaaaaattt ggcttaggaa tggtaacttc attttcagtt gccaaaggggt 600  
 agaaaaataa tatgtgtgtt gttatgttta tgttaacata ttattaggtta ctatctatga 660  
 atgtatttaa atatttttca tttctgtgta caagcattta taatttgcaa caagtggagt 720  
 ccatttagcc cagtgggaaa gtcttggaac tcaggttacc cttgaaggat atgctggcag 780  
 ccactctctt gatctgtgct taaactgtaa tttatagacc agctaaatcc ctaacttggg 840  
 tctggaatgc attagttatg ccttgtacca ttcccagaat ttcaggggca tctggtgttt 900  
 35 ggtctagtga ttgaaaacac aagaacagag agatccagct gaaaaagagt gatcctcaat 960  
 atcctaacta actggctctc aactcaagca gagtttcttc actctggcac tgtgatcatg 1020  
 aaacttagta gaggggattg tgtgtatttt atacaaattt aatacaatgt cttacattga 1080  
 taaaattctt aaagagcaaa actgcatttt atttctgcat ccacattcca atcatattag 1140  
 aactaagata tttatctatg aagatataaa tgggtgcagag agactttcat ctgtggattg 1200  
 cgttgtttct tagggttcct agcactgatg cctgcacaag catgtgatat gtgaaataaa 1260  
 40 atggattctt ctatagctaa atgagttccc tctggggaga gttctgggtac tgcaatcaca 1320  
 atgccagatg gtgtttatgg gctattttgt taagtaagtg gtaagatgct atgaagtaag 1380  
 tgtgtttgtt ttcattctat ggaactctt gatgcatgtg cttttgtatg gaataaattt 1440  
 tgggtgcaata tgatgtcatt caactttgca ttgaattgaa ttttgggtgt atttatatgt 1500  
 attatacctg tcacgcttct agttgcttca accattttat aaccattttt gtacatattt 1560  
 tacttgaaaa tattttaaat ggaaatttaa ataaacattt gatagtttac ataataaaaa 1620  
 45 aaaaaa

<210> 25  
 <211> 1420  
 <212> DNA  
 <213> Human

<400> 25

50 gttcagcatt gtttctgctt ctgaaatctg tatagtacac tggtttgtaa tcattatgtc 60  
 ttcattgaaa tccttgctac ttctcttctt cctcaatgaa agacacgaga gacaagagcg 120  
 acacaagctt aagaaaaacg agcaagggaag agtatcttca ttattctcat tttctctgag 180  
 55 ttggaacaaa aaacatgaag gactccaact agaagacaga tatttacatt taaatagatt 240  
 agtgggaaaa ctttaagagt ttccacatat tagttttcat tttttgagtc aagagactgc 300  
 tccttgtact gggagacact agtagtatat gtttgaatg ttactttaaa attatctttt 360

EP 1 166 798 A1

tattttataa ggcccataaa tactggttaa actctgttaa aagtgggcct tctatcttgg 420  
 atggtttcac tgccatcagc catgctgata tattagaaat ggcatcccta tctacttact 480  
 ttaagtctta aaattataca taaaatgctt tatttagaaa acctacatga tacagtgggtg 540  
 tcagccttgc catgtatcag ttctacttga aatttgagac caattaaatt tcaactgttt 600  
 aggggtggaga aagaggtact ggaaaacatg cagatgagga tatcttttat gtgcaacagt 660  
 atcctttgca tgggaggaga gttactcttg aaaggcaggc agcttaagtg gacaatgttt 720  
 tgatatagt tgagaatttt acgacacttt taaaaattgt gtaattgtta aatgtccagt 780  
 tttgctctgt tttgctgaa gttttagtat ttgttttcta ggtggacctc tgaaaaccaa 840  
 accagtacct ggggagggtta gatgtgtgtt tcaggcttgg agtgtatgag tggttttgct 900  
 tgtattttcc tccagagatt ttgaacttta ataattgcgt gtgtgttttt ttttttttaa 960  
 gtggctttgt tttttttct caagtaaaat tgtgaacata ttccctttat aggggcaggg 1020  
 catgagttag ggagactgaa gagtattgta gactgtacat gtgccttctt aatgtgtttc 1080  
 tcgacacatt ttttttcagt aacttgaaaa ttcaaaaagg acatttggtt aggttactgt 1140  
 acatcaatct atgcataaat ggcagcttgt ttctttgagc cactgtctaa attttgtttt 1200  
 tatagaaatt tttttactgt attgttccat agatggtcag tttgtacac agactgaaca 1260  
 atacagcact ttgccaaaaa tgagtgtagc attgtttaaa cattgtgtgt taacacctgt 1320  
 tctttgtaat tgggttgtgg tgcattttgc actacctgga gttacagttt tcaatctgtc 1380  
 agtaataaaa gtgtccttta acttcaaaaa aaaaaaaaaa

<210> 26  
 <211> 689  
 <212> DNA  
 <213> Human

<400> 26

aaacaaacaa aaaaaaagtt agtactgtat atgtaaatac tagcttttca atgtgctata 60  
 caaacaatta tagcacatcc ttccctttac tctgtctcac ctcccttagg tgagtacttc 120  
 cttaaataag tgctaatacat acatatacgg aacttgaaag ctttggttag ccttgcccta 180  
 ggtaatcagc ctagtttaca ctgtttccag ggagtagttg aattactata aaccattagc 240  
 cacttgtctc tgcaccattt atcacaccag gacagggtct ctcaacctgg gcgctactgt 300  
 catttggggc cagggtgatc ttccctgcaa gggctgtcct gtacctgccc gggcggccgc 360  
 tcgaagcgtg gtcgcggccg aggtactgaa aggaccaagg agctctggct gccctcagga 420  
 attccaaatg accgaaggaa caaagcttca gggctctggg tgggtgtctc cactattcag 480  
 gaggtggctg gaggtaacgc agcttcattt cgtccagtcc tttccagtat ttaaagttgt 540  
 tgtcaagatg ctgcattaaa tcaggcagggt ctacaaaggc atcccaagca tcaaacatgt 600  
 ctgtgatgaa gtaatcaatg aaacaccgga acctccgacc acctcctgaa tagtgggaga 660  
 cacacccaga gcctgaagtt tgtccttcg

<210> 27  
 <211> 471  
 <212> DNA  
 <213> Human

<400> 27

tcccagcggc atgaagtttg agattggcca ggccctgtac ctgggcttca tctccttcgt 60  
 cccctctcgt catttggtggc accctgcttt gcctgtcctg ccaggacgag gcaccctaca 120  
 agccctaacc caggccccgc ccagggccac cacgaccact gcaaacaccg cacctgccta 180  
 ccagccacca gctgcctaca aagacaatcg ggccccctca gtgacctcgg ccaccacagc 240  
 gggtagagge tgaacgacta cgtgtgagtc cccacagcct gcttctcccc tgggctgtgt 300  
 tgggctgtgt cccggcgagg ctgtcaatgg aggcagggtt tccagcaca agtttacttc 360  
 tgggcaattt ttgtatccaa ggaaataatg tgaatgcgag gaaatgtct tagagcacag 420  
 ggacagaggg ggaaataaga ggaggagaaa gctctctata ccaaagactg a

<210> 28  
 <211> 929  
 <212> DNA  
 <213> Human

<400> 28

ggatgaactca gtgcattggg ccaatgggtc gacacaggct ctgccagcca caaccatcct 60  
 gctgcttctg acgggttggc tgtctgtggg ctttccctc actgtcattg gaggcattct 120  
 tgggaagaac aacgccagcc cttttgatgc accctgtcgc accaagaaca tcgcccggga 180  
 gattccaccc cagccctggt acaagtctac tgtcatccac atgactgttg gaggcttcct 240

gcctttcagt gccatctctg tggagctgta ctacatcttt gccacagtat ggggtcggga 300  
gcagtacact ttgtacggca tcctcttctt tgtcttcgcc atcctgctga gtgtgggggc 360  
ttgcatctcc attgcactca cctacttcca gttgtctggg gaggattacc gctgggtggtg 420  
5 gcgatctgtg ctgagtgttg gctccacogg cctcttcac ttcctctact cagttttcta 480  
ttatgcccg cgctccaaca tgtctggggc agtacagaca gtagagttct tcggctactc 540  
cttactcact ggttatgtct tcttctcat gctgggcacc atctcctttt tttcttccct 600  
aaagttcatc cggatatct atgttaacct caagatggac tgagttctgt atggcagaac 660  
tattgctgtt ctctcccttt ctctatgccc tgttgaactc tcctaccagc ttctcttctg 720  
attgactgaa ttgtgtgatg gcattgttgc cttccctttt tccctttggg cattccttcc 780  
10 ccagagaggg cctggaaatt ataaatctct atcacataag gattatata ttgaactttt 840  
taagttgcct ttagttttgg tctgtatttt tctttttaca attaccaaaa taaaatttat 900  
taagaaaaag aaaaaaaaaa aaaaaaaaaa

<210> 29  
<211> 1775  
<212> DNA  
15 <213> Human

<400> 29.

gaacgtgatg ggaacttttg gaggatgtct gagaaaaatgt ccgaagggat tttggccaac 60  
20 accagaaaaac gccaatgtcc taggaattcc ctcccaaat gcttcccaaa aaattactca 120  
ttgacaattc aaattgcact tgggtggcgg cagcccgggc ggcttcagt ccgtgtgggg 180  
cgcccgctg gccttctcct cgtaggactc cccaaactcg ttactctgc gtttatccac 240  
aggataaagc caccgctggt acaggtagac cagaaacacc acgtcgtccc ggaagcaggc 300  
cagccggtga gacgtgggca tgggtgatg gaaggcaag acgtcatcaa tgaagggtgtt 360  
gaaagccttg taggtgaagg ccttcaggag catagtgtcc actgacttca acttgtagtt 420  
25 cacaagagc tggggcagca tgaagaggaa accaaaggca tagaccctgt tgacgaagct 480  
gttgattaac caggagtacc agctcttata tttgatattc aggagtgaat agacagcacc 540  
ccgacacag agagggtaca gcaggtatga caagtacttc atggcctgag tatcgtactc 600  
ctcgttttct ctctcagatt gcgtgtaagt gccaaactga aattcgggca tcaggcctct 660  
ccaaaaata gtcatcttca atgccttctt cactttccac agctcaatgg cggctccaac 720  
accgcgcggg accagcacca gcaggctcgt ctgctcgtcc agcaggaaca gaaagatgac 780  
30 caggtgctg aagcagcgcc agagcactgc cttggtggac atgccgatca tgctcttctt 840  
cttcttccag aaactgatgt catttttaaa ggccaggaaa tcaagagaa gatggaacgc 900  
tgcgacaaag aaggtcagcg ccagggaagta taagttggta tctacaaaaa ttcctttcac 960  
ctcatcagca tctttctctg aaaaccggaa ctgctgcagg gagtacacgg cgtcctgcat 1020  
gtggatccag aagcgcagcc gccccagtga gaccttgcg taggacacgg tgaggggcag 1080  
ctcgtgtgtg gagcgtttta tgaccatcag gtccttcacg cggttgctga gctggctgat 1140  
35 gaacaggatg ggcaggtaat gcacggtttt ccccgctgg atcatcttca tgtaccgatg 1200  
cacatcggca ggcaggagg acccgtaaaa gacaaagtgt tccgccatca cgttcagcgc 1260  
cagcccggt cgccagtgg acactggctc atccagggca ctgctcggct tcttctcgcg 1320  
ctcgtatctg tgtgtatcag actccccgtg gagcaggttg atttcttctg gcttggggac 1380  
catgtagggt gtcagaggac tgaccagggt cacctgcttc ccgtcgtgcc acggcaggac 1440  
cccagcgtga tggaggaaga tgtaggcata cagcgtccca ttgtttctcg ttttctttgg 1500  
40 tacagaaaca ttaactgtcc tttcaaat tgaactcaca tcaaaagtct ccacattcaa 1560  
gaccaggtcg atgtgttct cagcaccag gtgggacctc gtcgtggtgt acacgctcag 1620  
ctgcagcttg ggccgcgcg ccaggtaggg ctggatgcag ttggcgtcgc cggagcacgg 1680  
gcgggtgtag acgatgccgt acatgacca gcaggtgtgc accacgtaga ccacgaacac 1740  
gccaccacc aagctggtga aggagctgcg gcccc

<210> 30.  
45 <211> 1546  
<212> DNA  
<213> Human

<400> 30

50 aaaataagta ggaatgggca gtgggtattc acattcacta cacccttttcc atttgctaatt 60  
aaggccctgc caggctggga gggaattgtc cctgcctgct tctggagaaa gaagatattg 120  
acaccatcta cgggcacat ggaactgctt caagtacca ttctttttct tctgccagt 180  
atattgcagca gtaacagcac aggtgtttta gaggcagcta ataattcact tgttgttact 240  
55 acaacaaaac catctataac aacacaaaac acagaatcat tacagaaaaa tgttgtcaca 300  
ccaacaactg gaacaactcc taaaggaaca atcaccaatg aattacttaa aatgtctctg 360  
atgtcaacag ctactttttt aacaagtaaa gatgaaggat tgaaagccac aaccactgat 420



gtcaggaaga atgactccat catttcaaac gtaacagtaa caagtgttac acttccaaat 480  
 gctgtttcaa cattacaaag ttccaaaccc aagactgaaa ctcagagttc aattaaaaca 540  
 acagaaatac caggtagtgt tctacaacca gatgcatcac cttctaaaac tggtagatta 600  
 5 acctcaatac cagttacaat tccagaaaac acctcacagt ctcaagtaat aggcactgag 660  
 ggtggaaaaa atgcaagcac ttcagcaacc agccggtctt attccagtat tattttgccc 720  
 gtggttattg ctttgattgt aataacactt tcagtatttg ttctgggtgg tttgtaccga 780  
 atgtgctgga aggcagatcc gggcacacca gaaaatggaa atgatcaacc tcagtctgat 840  
 aaagagagcg tgaagcttct taccgttaag acaatttctc atgagtctgg tgagcactct 900  
 gcacaaggaa aaaccaagaa ctgacagctt gaggaattct ctccacacct aggcataat 960  
 10 tacgcttaat cttcagcttc tatgcaccaa gcgtggaaaa ggagaaagtc ctgcagaatc 1020  
 aatcccagact tccatacctg ctgctggact gtaccagacg tctgtcccag taaagtgtg 1080  
 tccagctgac atgcaataat ttgatggaat caaaaagaac cccggggctc tctgttctc 1140  
 tcacatttaa aaattccatt actccattta caggagcgtt cctaggaaaa ggaattttag 1200  
 gaggagaatt gttagcagt gaattcgaca gccaggagg tgggctcgct gataggcatg 1260  
 actttcctta atgtttaaag ttttccgggc caagaatttt tatccatgaa gactttecta 1320  
 cttttctcgg tgttcttata ttacctactg ttagtattta ttgtttacca ctatgttaat 1380  
 15 gcagggaaaaa gttgcacgtg tattattaaa tattaggtag aaatcatacc atgctacttt 1440  
 gtacatataa gtattttatt cctgctttcg tgttactttt aataataaac tactgtactc 1500  
 aataactctaa aaatactata acatgactgt gaaaatggca aaaaaa

<210> 31  
 <211> 750  
 20 <212> DNA  
 <213> Human

<400> 31

cacttgggca ccccccatttt ctaaaaaaat ggaaatctgg agggcaaaaa aggtgtgctg 60  
 25 aagggaagtg cctctgatgg cccaaaaacc ttcttccaaa ctagtgtagg aatggaatgg 120  
 atagcaaatg gatccttttt ggccctcttt ggagcatgcc ttccctatct tatccttggc 180  
 cccactaaag cagaacgtta cggatatttc tgtttttgcc attggatgcc tatctggcca 240  
 aacagccttt ccctaattgg aaaatgcagt cctgtttaaa acctttgatt tacgactact 300  
 tgtacatgct tgctcattac aattttgaca ttttttacct agtgaagacc ccaaaccat 360  
 30 cagtgaatac tgacaagatc ataaagaaca gtatcatatt attatttagt cgcttttaca 420  
 gtggcaagcc aattttgaaa tatctcattt aaaaactcaga cccaattcac tgagtatac 480  
 ttttaaatagc ttctctcagca cactatttcc catgcattaa atatgataaa ataactctatc 540  
 actgcccacg gtccttgtta aaaggaagtc tgaatacaga gccacaaca ctaaaattgt 600  
 ttttctagct acaaaagtata gcatcatcaa cacagacacg atttggactc cctgacaggt 660  
 ggattggaaa acggtgttta aagagaagag aacattttta cataaatgct attaagaatc 720  
 35 ccaaaggcct tatttgtcac caccgtcccg

<210> 32  
 <211> 1620  
 <212> DNA  
 <213> Human

<400> 32

gcaattcccc cctcccacta aacgactccc agtaattatg tttacaaccc attggaatgca 60  
 gtgcagccat tcataagaac ctgtgtgccc cagaaaaatc tgtccttttt ggtaccaaac 120  
 ctgagggtctt ttggaagata atgtagaaaa ccactaccta ttgaaggcct gttttggcta 180  
 45 atctgtgcaa actctgatga tacctgcctt atgtggattc ttttccacac tgctttcatt 240  
 ttttaagtata aagacttaga aaactagaat aatgctttta caaataatta aaagtatgtg 300  
 atgttctggg ttttttccct ctttttagaa cccgcctcc atttaaaaaa ttaaaaaaaa 360  
 aaaaaaaact ttttaacatt aaaaaataaa aattaacaaa atttcaacta ttccaggaca 420  
 cgctggcatt tggactcaat gaaaagggca cctaagaaa ataaggctga ctgaatgttt 480  
 tccataattt tcacacaata acagtccctt tctatccagc ttgccttcca tttatctcta 540  
 ggggttagctt ttcaggcaac atccttggtc attgccaga aagtacctga gctatcagtg 600  
 50 attggaatgg cacaggaac cgaatcacat ggggtgccct cccttgggtt tcaagtatct 660  
 tggagttgtg cacaaaaatt aggtcatgcc ttcaagtgtc tgttctttta acctaccctt 720  
 tgacaatcag gtgctaataa tttataacta ttaaaaccag cacataagta ttgtaaatgt 780  
 gtgttccctc taggttgaaa gaaatgtctt tccttctatc tgggtcctgt taaagcgggt 840  
 gtcagttgtg tcttttccac tcgattttgt aattaataga attgggggga gaggaatga 900  
 tgatgtcaat taagtttcag gtttggcatg atcatcatc tcgatgatat tctcactttg 960  
 55 tcgcaaatct gcccttatcg taagaacaag ttccagaatt ttccctccac tatacagactc 1020  
 cagtattatg tttacaatcc attggaatgag tgcagcatta taagaccttg gtgccagaa 1080

EP 1 166 798 A1

aaatctgtcc tttttggtac caaacctgag gtcttttga agataatgta gaaaaccact 1140  
 acctattgaa ggcctgtttt ggctaactct tgcaaaactct gatgatacct gcttatgtgg 1200  
 attcttttcc acactgcttt catttttaag tataaagact tagaaaacta gaataatgct 1260  
 tttacaataa attaaaagta tgtgatgttc tgggtttttt ccttcttttt agaaccctgt 1320  
 atttaaacaa gccttctttt taagtcttgt ttgaaattta agtctcagat cttctggata 1380  
 ccaaatacaa aacccaacgc gtaaacacag gcagtatttg tgttcctaata tttaaaaage 1440  
 tttatgtata ctctataaat atagatgcat aaacaacact tccccttgag tagcacatca 1500  
 acatacagca ttgtacatta caatgaaat gtgtaactta aggggtattat atatataaat 1560  
 acatatatac ctttgaacc tttatactgt aaataaaaaa gttgctttag tcaaaaaaaa 1620

<210> 33  
 <211> 2968  
 <212> DNA  
 <213> Human

<400> 33

gaaaaagtag aaggaaacac agttcatata gaagtaaaag aaaaccctga agaggaggag 60  
 gaggaggag aagagggaaga agaagatgaa gaaagtgaag agggaggagga agaggaggga 120  
 gaaagtgaag gcagtgaagg tgaatgaggaa gatgaaaagg tgtcagatga gaaggattca 180  
 gggaagacat tagataaaaa gccaaagtaaa gaaatgagct cagattctga atatgactct 240  
 gaagctgata ggactaaaag agaaaagggt tatgacaaaag caaaacggag gattgagaaa 300  
 cggcgacttg aacatagtaa aaatgtaaac accgaaaagc taagagcccc tattatctgc 360  
 gtacttgggc atgtggacac aggggaagaca aaaattctag ataagctccg tcacacacat 420  
 gtacaagatg gtgaagcagg tggatcacca caacaatttg gggccaccaa tgttctctct 480  
 gaagctatta atgaacagac taagatgatt aaaaattttg atagagagaa tgtacggatt 540  
 ccaggaaatgc taattattga tactcctggg catgaatctt tcagtaatct gagaaataga 600  
 ggaagctctc tttgtgacat tgccatttta gttgttgata ttatgcatgg ttggagccc 660  
 cagacaattg agtctatcaa ccttctcaaa tctaaaaaat gtcccttcat tgttgactc 720  
 aataagattg ataggttata tgattggaaa aagagtcctg actctgatgt ggctgctact 780  
 ttaaagaagc agaaaaagaa tacaaaagat gaatttgagg agcgagcaaa ggctattatt 840  
 gtagaatttg cacagcaggg tttgaatgct gctttgtttt atgagaataa agatccccgc 900  
 acttttgtgt ctttgggtacc tacctctgca catactggtg atggcatggg aagctctgac 960  
 taccctcttg ttgagcaaga ttgagcaaga gacttgaca ctgtgaagag 1020  
 ctgagagcac aggtgatgga ggttaaagct ctcccgggga tgggcaccac tatagatgtc 1080  
 atcttgatca atgggcgttt gaaggaaagga gatacaatca ttgttccctg agtagaaggg 1140  
 cccattgtaa ctgagattcg aggcctcctg ttacctcctc ctatgaagga attacgagt 1200  
 aagaaccagt atgaaaagca taaaagaagta gaagcagctc agggggtaaa gattcttgga 1260  
 aaagacctgg agaaaacatt ggctgggtta cccctccttg tggcttataa agaagatgaa 1320  
 atccctgttc ttaaagatga attgatccat gagttaaagc agacactaaa tgcatacaaa 1380  
 ttagaagaaa aaggagtcta tgtccaggca tctacactgg gttctttgga agctctactg 1440  
 gaatttctga aaacatcaga agtgccctat gcaggaatta acattggccc agtgcataaa 1500  
 aaagatgtta tgaaggcttc agtgatgttg gaacatgacc ctgagatgc agtaattttg 1560  
 gccttcgatg tgagaattga acgagatgca caagaaatgg ctgatatgtt agggagttga 1620  
 atttttagtg cagaaattat ttatcattta tttgatgcct ttacaaaata tagacaagac 1680  
 tacaagaac agaaacaaga agaatttaag cacatagcag tatttccctg caagataaaa 1740  
 atcctccctc agtacatttt taattctcga gatccgatag tgatgggggt gacgggtgaa 1800  
 gcaggctcagg tgaacacagg gacacccatg tgtgtcccaa gcaaaaattt tgttgacatc 1860  
 ggaatagtta caagtattga aataaaccat aaacaagtgg atgttgcaaa aaaaggacaa 1920  
 gaagtttggtg taaaaataga acctatccct ggtgagtcac ccaaaatggt tggagacat 1980  
 tttgaagcta cagatattct tgtagtaag atcagccggc agtccattga tgcactcaaa 2040  
 gactggttca gagatgaaat gcagaagagt gactggcagc ttatttgga gctgaagaaa 2100  
 gtatttgaaa tcatctaatt ttttcacatg gagcaggaac tggagtaaat gcaatactgt 2160  
 gttgtaatat cccaacaaaa atcagacaaa aaatggaaca gacgtatttg gacactgatg 2220  
 gacttaagta tggaaaggaag aaaaataggt gtataaaatg ttttccatga gaaaccaaga 2280  
 aacttacact ggttgacag tggtcagtta catgtcccca cagttccaat gtgctgttc 2340  
 actcacctct ccttcccca acccttctct acttggtgc tgttttaaag tttgcccttc 2400  
 cccaaatttg gatttttatt acagatctaa agctctttcg attttatact gattaaatca 2460  
 gtactgcagt atttgattaa aaaaaaaaaa gcagattttg tgattcttg gactttttt 2520  
 acgtaagaaa tacttcttta tttatgcata ttcttccac agtgattttt ccagcattct 2580  
 tctgccatat gcctttaggg cttttataaa atagaaaatt aggcattctg atatttctt 2640  
 agctgctttg tgtgaaacca tgggtgaaaa gcacagctgg ctgcttttta ctgctgtgt 2700  
 agtcacagag ccattgtaat catcacaaat ctaaaacaaa ctaccaataa agaaaaacaga 2760  
 catccaccag taagcaagct ctgttagggt tccatgggta gtggtagctt ctctcccaca 2820  
 agttgtctc ctaggacaag gaattatctt aacaaactaa actatccatc acactacctt 2880  
 ggtatgccag cactgggta acagtaggag attttataca ttaactctgat ctgtttaatc 2940

tgatcgggtt agtagagatt ttatacat

<210> 34  
 <211> 6011  
 <212> DNA  
 <213> Human

<400> 34

acggggcgcc ggacgacccg cacatcttat cctccacgcc ccactcgac tcggagcggg 60  
 accgccccgg actccccctc gggcgggcca ctcgaggagt gaggagagag gccgccggcc 120  
 cggcttgagc cgagcgagc accccccgcg ccccgcgcca gaagtttggt tgaaccgggc 180  
 tgccgggaga aacttttttc ttttttcccc ctctcccggg agagtctctg gaggaggagg 240  
 ggaactcccc cggcccaagg ctggtgggct cggggtcgcg cggccgcaga aggggagggg 300  
 tccgcccgcg aggggaggcg ccccggggga cccgagaggg gggtagggac cgcgggctgc 360  
 tgggtcgggc gcggcagcgt gtccccgcg caggggaggc gccgccccgc tcccggccc 420  
 gctgcgagga ggaggcgcg gcggcgagc aggatgtact tgggtggcgg ggacaggggg 480  
 ttggcggcgt gcgggcacct cctggtctcg ctgctggggc tgcctgctgc gccggcgcg 540  
 tccgaccccc gggcgctggg ctgcctgcc tgtgacgagt ccaagtgcga ggagcccagg 600  
 aaccgcccgg ggagcatcgt gcaggcgctc tgcggctgct gctacacgtg cgcagccag 660  
 gggaacgaga gctgcgcgcg cactctcggg atttacggaa cctgcgaccg ggggctgcgt 720  
 tgtgtcatcc gcccccgcgt caatggcgac tccctcaccg agtacgaagc gggcgtttgc 780  
 gaagatgaga actggactga tgaccaactg cttggtttta aaccatgcaa tgaaaacctt 840  
 attgctggct gcaatataat caatgggaaa tgtgaatgta acaccattcg aacctgcagc 900  
 aatccctttg agtttccaa tcaggatatg tgcctttcag ctttaaagag aattgaagaa 960  
 gagaagccag attgctccaa ggcccgctgt gaagtccagt tctctccacg ttgtcctgaa 1020  
 gattctgttc tgatcgaggg ttatgctcct cctggggagt gctgtccctt acccagccgc 1080  
 tgcgtgtgca accccgcagg ctgtctgcgc aaagtctgcc agccgggaaa cctgaacata 1140  
 ctagtgtcaa aagcctcagg gaagccggga gagtgtgtg acctctatga gtgcaacca 1200  
 gttttcggcg tggactgcag gactgtggaa tgcctactg ttcagcagac cgcgtgtccc 1260  
 ccggacagct atgaaactca agtcagacta actgcagatg gttgtgttac ttgccaaca 1320  
 agatgcgagt gtctctctgg cttatgttgt ttcccctgtg gtgaggtggg atccactccc 1380  
 cgcatagtct ctcggtggca tgggacacct ggaaagtgt gtgatgtctt tgaatgtgtt 1440  
 aatgatacaa agccagcctg cgtatttaac aatgtggaat attatgatgg agacatgttt 1500  
 cgaatggaca actgtcgggt ctgtcgatgc caagggggcg ttgccatctg cttcaccgcc 1560  
 cagtgtgggt agataaactg cgagaggtac tacgtgcccc aaggagagtg ctgcccagtg 1620  
 tgtgaagatc cagtgtatcc ttttaataat cccgctggct gctatgcaa tggcctgatc 1680  
 ctggcccacg gagaccggtg gcgggaagac gactgcacat tctgccagtg cgtcaacggt 1740  
 gaacgccact gcgttgcgac cgtctgcgga cagacctgca caaacctgt gaaagtgcct 1800  
 ggggagtgtt gccctgtgtg cgaagaacca accatcatca cagttgatcc acctgcatgt 1860  
 ggggagttat caaactgcac ctgacacgg aaggactgca ttaatggttt caaacgcgt 1920  
 cacaatgggt gtcggacctg tcagtgcata aacacccagg aactatgttc agaacgtaa 1980  
 caaggctgca ccttgaaactg tcccttcggt ttccctactg atgccaaaa ctgtgagatc 2040  
 tgtgagtgcc gcccaggcc caagaagtgc agaccataa tctgtgacaa gtattgtcca 2100  
 cttggattgc tgaagaataa gcacggctgt gacatctgtc gctgtaagaa atgtccagag 2160  
 ctctcatgca gtaagatctg ccccttgggt ttccagcagg acagtacgg ctgtcttatc 2220  
 tgcaagtgca gagaggcctc tgcctcagct gggccacca tcctgtcggg cacttgtctc 2280  
 accgtggatg gtcacatca taaaaatgag gagagctggc acgatgggtg ccgggaatgc 2340  
 tactgtctca atggacggga aatgtgtgcc ctgatcacct gccgggtgcc tgcctgtggc 2400  
 aacccacca ttcaccctgg acagtgtgc ccatcatgtg cagatgactt tgtggtgcag 2460  
 aagccagagc tcagtactcc ctccatttgc cacgcccctg gaggagaata ctttgtggaa 2520  
 ggagaaacgt ggaacattga ctctgtact cagtgcacct gccacagcgg acgggtgctg 2580  
 tgtgagacag aggtgtgccc accgctgctc tgccagaacc cctcacgcac ccaggattcc 2640  
 tgcgtccccc agtgtacaga tcaacctttt cggccttcct tgtcccga taacagcgta 2700  
 cctaattact gcaaaaatga tgaaggggat atattcctgg cagctgagtc ctggaagcct 2760  
 gacgtttgta ccagctgcat ctgcattgat agectaatta gctgtttctc tgagtcctgc 2820  
 ccttctgtat cctgtgaaag acctgtcttg agaaaaggcc agtgtgtcc ctactgcata 2880  
 aaagacacaa ttccaaagaa ggtgtgtgac cacttcagtg ggaaggccta tgccgacgag 2940  
 gagcgtggg accttgacag ctgcacccac tgctactgcc tgcagggcca gacctctgc 3000  
 tgcacgtca cgtgcccccc tctgcccctg gttgagccca tcaacgtgga aggaagtgc 3060  
 tgcccaatgt gtccagaaat gtatgtccca gaaccaacca atatacccat tgagaagaca 3120  
 aaccatcgag gagaggttga cctggaggtt cccctgtggc ccacgcctag tgaaaatgat 3180  
 atcgtccatc tccctagaga tatgggtcac ctccaggtag attacagaga taacaggctg 3240

caccceaagtg aagattcttc actggactcc attgctcag ttgtggttcc cataattata 3300  
 tgcctctcta ttataatagc attcctattc atcaatcaga agaaacagtg gataccactg 3360  
 ctttgctggt atcgaaacacc aactaagcct tcttccttaa ataactcagct agtatctgtg 3420  
 gactgcaaga aaggaaccag agtccaggtg gacagttccc agagaatgct aagaattgca 3480  
 gaaccagatg caagattcag tggtctctac agcatgcaaa aacagaacca tctacaggca 3540  
 gacaatttct accaaacagt gtgaagaaa gcaactagga tgagggttca aaagacggaa 3600  
 gacgactaaa tctgctctaa aaagtaaaact agaatttgtg cacttgctta gtggattgta 3660  
 ttggattgtg acttgatgta cagcgctaag accttactgg gatgggctct gtctacagca 3720  
 atgtgcagaa caagcattcc cacttttccct caagataact gaccaagtgt tttcttagaa 3780  
 ccaaagtttt taaagtgtct aagatatatt tgctgtgtaag atagctgtag agatatttgg 3840  
 ggtggggaca gtgagtttgg atggggaaag ggggtggagg gtggtgttgg gaagaaaaat 3900  
 tggtcagctt ggctcgggga gaaacctggt aacataaaa cagttcagtg gccagaggtg 3960  
 tatttttttc ctattgctct gaagactgca ctggttgcctg caaagctcag gcctgaatga 4020  
 gcaggaaaca aaaaagccct tgcgaccag ctgccataac caccttagaa ctaccagacg 4080  
 agcacatcag aaccttttga cagccatccc aggtctaaa ccacaagttt cttttctata 4140  
 gactcaccag cttctcgagg agtgaggaa ccagagaaa gcgatagcgg catttctcta 4200  
 aagcgggtta ttaaggatat atacagttac acttttggct gcttttattt tcttccaagc 4260  
 caatcaatca gccagttcct agcagagtca gcacatgaac aagatctaag tcatctcttg 4320  
 atgtgagcac tggagctttt tttttttaca acgtgacagg aagaggaggg agagggtgac 4380  
 gaaccaccag cattccggga ggttatattt cactgtttgt tgttgccttg ttctgttata 4440  
 ttgttggttg ttcatagttt ttgtgaagc tctagcttaa gaagaaactt tttttaaaaa 4500  
 gactgttttg ggattctttt tctttattat atactgattc taaaaaatag aaactacttc 4560  
 attttaattg tatattattc aagcactttt gttgaagctc aaaaaaatg atgctctttt 4620  
 aaacttttagc aattatagga gtatttatgt aactatctta tgcttcaaaa aacaaaagta 4680  
 tttgtgtgca tgtgtatata atatatatat atacatatat atttatacac atacaattta 4740  
 tgttttctctg ttgaatgtat ttttatgaga ttttaaccag aacaaaggca gataaacagg 4800  
 cattccatag cagtgccttt gatcacttac aaattttttg aataacacaa aatctcattc 4860  
 tacctgcagt ttaattggaa agatgtgtgt gtgagagtat gtatgtgtgt gtgtgtgtgt 4920  
 gtgtgtgccc gcgcacgcac gccttgagca gtcagcattg cacctgctat ggagaagggt 4980  
 attcctttat taaaatcttc ctcatittga tttgctttca gttggttttc aatttgctca 5040  
 ctggccagag acattgatgg cagttcttat ctgcatcact aatcagctcc tggatttttt 5100  
 tttttttttt tcaaaccaatg gtttgaaca actactggaa tattgtccac aataagctgg 5160  
 aagtttgttg tagtatgcct caaatataac tgactgtata ctatagtggt aacttttcaa 5220  
 acagccctta gcacttttat actaatatac ccatttgtgc attgagtttt cttttaaaaa 5280  
 tgcttgttgt gaaagacaca gataccagc atgcttaacg tgaaaagaaa atgtgttctg 5340  
 tttttaaag gaactttcaa gtattgttgt aaataacttg acagagggtg ctgaacttta 5400  
 aaaaaaatta atttattatt ataagacct aatttattaa tctgaagatt aaccattttt 5460  
 ttgtcttaga atatcaaaaa gaaaaagaaa aaggtgttct agctgtttgc atcaaaggaa 5520  
 aaaaagattt attatcaagg ggcaatattt ttatcttttc caaaaataat ttgttaatga 5580  
 tacattacaa aaatagattg acatcagcct gattagtata aattttgttg gtaattaatc 5640  
 cattctggc ataaaaagtc tttatcaaaa aaaattgtag atgcttgctt tttgtttttt 5700  
 caatcatggc catattatga aaatactaac aggatatagg acaagggtga aattttttta 5760  
 ttattatttt aaagatatga ttatcctga gtgctgtatc tattactctt ttacttgggt 5820  
 tctgtgtgtg ctcttgtaaa agaaaaatat aatttcctga agaataaaat agatatatgg 5880  
 cacttggagt gcatcatagt tctacagttt gttttgttt tcttcaaaaa agctgtaaga 5940  
 gaattatctg caacttgatt cttggcagga aataaacatt ttgagttgaa atcaaaaaaa 6000  
 aaaaaaaaaa a

<210> 34a  
 <211> 1036  
 <212> DNA  
 <213> Human

<400> 34a

mylvagdrgl agcghllvsl lglillpars gtralvclpc deskceepn rpgsivqgvc 60  
 gccytcasgg nescggtfgi ygtcdrglrc virpplngds lteyeagvce denwtddqll 120  
 gfkpcnenli agcniingkc ecntirtcsn pfefpsqdmc lsalkrieee kpdcskarce 180  
 vqfSprcped svlliegyapp geccpLpsrc vcnpagclrk vcqpgnlnil vskasgkpgc 240  
 ccdlyeckpv fgvdcrvvec ptvqqtacpp dsyetqvrIt adgcctlprr ceclsglcf 300  
 pvcevgtpr ivsrgdgtpg kccdvfecvn dtkpacvfnv veyydgdmfr mdncrfrcq 360  
 ggvaicftaq cgeinceryy vpegeccpvc edpvpfnnp agcyanglil ahgdrwredd 420  
 ctfccqcnve ngcavatvcgq tctnrvkvpg eccpvceepT iitvdppacg elsnctltkr 480  
 dcimgfkrdh ngcrtccqcin tqelcserkq gctlnpcfgf ltdaqnceic ecrprpkkr 540

EP 1 166 798 A1

piicdkycpl gllknkhgced icrckkcpel scskicplgf qqdshgclie kcreasasag 600  
 ppilsgtclt vdghhhknee swhdgcrecy clngremcal itcpvpacgn ptihpggccp 660  
 scaddfvvqk pelstpsich apggeyfvveg etwnidsctq ctchsgrvlc etevcppllc 720  
 qnpsrtqdsq cpqctdqpfir pslsrnnsvp nyckndegdi flaaeswkpd vctscicids 780  
 viscfesecp svscerpvlr kgqccpycik dtipkkvch fsgkayadee rwdldscthc 840  
 yclqggtlcs tvscpplpcv epinvegscs pmcpemyvpe ptnipiektn hrgevdlevp 900  
 lwptpsendi vhlprdmghl qvdyrdnrlh psedssldsi asvvvpiic lsiiiaflfi 960  
 nqkkqwipll cwyrtptkps slnnqlvsvd ckkgttrvqvd ssqrmlriae pdarfsgfys 1020  
 mqkqnhlqad nfyqtv

<210> 35  
 <211> 716  
 <212> DNA  
 <213> Human

<400> 35

gcagtagctg gagggtcctg cagggggaaa gcgaaccggg ccctgaagtc cggggcagtc 60  
 acccgggggt cctggggccgc tctggccggg tggggctgag cagcgatcct gctttgtccc 120  
 agaagtcag agggatcagc ccagaaacac accctcctcc cggggacgcc gcagctttct 180  
 ggaggctgag gaaggcatga agagtggtg ccaactgctg gccgactgag aaaagaattt 240  
 ccagaactcg gtctattttt acagattgag aaactatggt tcaagaagag aggacggggc 300  
 ttgaggggat ctctgtatgc tccttatatg acctcaaac gaccatacta aacagtgtag 360  
 aagggtcttt taaggctcta aatgtcaggg tctcccatcc cctgatgcct gacttgtaga 420  
 gtcagtggtg agtagacggg ttcctccacc cagggttgac tcagggggat gatctgggtc 480  
 ccattctggt ctttaagacc caaacaaggg ttttttcagc tccaggatct ggagcctcta 540  
 tctggttagt gtcgtaacct ctgtgtgcct cccgttacc catctgtcca gtgagctcag 600  
 ccccatcca cctaacaggg tggccacagg gattactgag ggtaagacc ttagaactgg 660  
 gtctagcacc cgataagagc tcaataaatg ttgttccttt ccacatcaaa aaaaaa

<210> 36  
 <211> 395  
 <212> DNA  
 <213> Human

<400> 36

ccaatacttc attcttcatt ggtggagaag attgtagact tctaagcatt ttccaaataa 60  
 aaaagctatg atttgatttc caacttttaa acattgcatg tcctttgcca ttactacat 120  
 tctccaaaaa aaccttgaaa tgaagaaggc cacccttaaa atacttcaga ggctgaaaat 180  
 atgattatta cattggaatc ctttagccta tgtgatattt ctttaacttt gcactttcac 240  
 gccagtaaaa accaaagtca gggtaaccaa tgtcatttta caaaatgtta aaaccctaata 300  
 tgagttcct tttttaaatt attttaaaga ttacttaaca acattagaca gtgcaaaaaa 360  
 agaagcaagg aaagcattct taattctacc atcct

<210> 37  
 <211> 134  
 <212> DNA  
 <213> Human

<400> 37

ccctcgagcg gccgcccggg caggtagctt taccaccgaa ttgttcactt gactttaaga 60  
 aaccataaaa gctgcctggc tttagcaaac aggcctatca acaccatggt gactctccat 120  
 aagggacacc gtgt

<210> 38  
 <211> 644  
 <212> DNA  
 <213> Human

<400> 38

aagcctgttg tcatggggga ggtggtggcg cttggtggcc actggcgccc gaggtagagg 60

EP 1 166 798 A1

cagtggcgct tgagttggtc gggggcagcg gcagatttga ggcttaagca acttcttccg 120  
 ggggaagagt ccagtgacgc cactgttaca attcaagatc ttgatctata tccatagatt 180  
 ggaatatattg tggggccagca atccctcagac gcctcactta ggacaaatga ggaaactgag 240  
 gcttggtgaa gttacgaaac ttgtccaaaa tcacacaact tgtaaagggc acagccaaga 300  
 ttcagagcca ggctgtaaaa attaaatga acaaattacg gcaaagtttt aggagaaaaga 360  
 aggatgttta tgttccagag gccagtcgtc cacatcagtg gcagacagat gaagaaggcg 420  
 ttcgcaccgg aaaatgtagc ttcccgggta agtaccttgg ccatgtagaa gttgatgaat 480  
 caagaggaat gcacatctgt gaagatgctg taaaaagatt gaaagctgaa aggaagtctt 540  
 tcaaaggctt ctttgaaaaa actggaaaaga aagcagttaa agcagtttct gtgggtctaa 600  
 gcagatggac tcagaggttg tggatgaaaa actaaggacc tcac

<210> 39  
 <211> 657  
 <212> DNA  
 <213> Human

<400> 39

ctttttgttt gggttttcca atgtagatgt ctacgtgaaa tgtgcagata tactttgttc 60  
 cttatatggt caccagtgtt aattatggac aaatacatta aaacaagggt tcctggccca 120  
 gcctcccac taatctcttt gatactcttg gaatctaagt ctgaggagcg atttctgaat 180  
 tagccagtgt tgtaccaact ttctgttagg aattgtatta gaataacctt tctttttcag 240  
 acctgctcag tgagacatct tggggaatga agtaggaaaa tagacatttg gtggaaaaac 300  
 agcaaaatga gaacattaaa aagactcatt caagtatgag tataaagggt atggaaattc 360  
 tgggtcctttg agcaaaatga gaagaaaaaa ttctgctcag cagtattcac tgtgttaaga 420  
 ttttttgttt tttacacgaa tggaaaaatg atgtgtaagt ggtatagatt ttaatcagct 480  
 aacagtcact ccagagattt tgatcagcac caattcctat agtagtaagt atttaaaagt 540  
 taagaaatac tactacattt aacattataa agtagagttc tggacataac tgaaaattag 600  
 atgtttgctt caatagaaat ttgttccac ttgtattttc aacaaaatta tcggaac

<210> 40  
 <211> 1328  
 <212> DNA  
 <213> Human

<400> 40

acaattttta aataactagc aattaatcac agcatatcag gaaaaagtac acagtgaatt 60  
 ctggttagtt tttgtaggct cattatggtt aggtcggtta agatgtatat aagaacctac 120  
 ctatcatgct gtatgtatca ctcatccat ttcatgttc catgcatact cgggcatcat 180  
 gctaataatgt atccttttaa gcactctcaa ggaacaaaaa gggcctttta tttttataaa 240  
 ggtaaaaaaa attcccaaaa tttttgcac tgaatgtacc aaaggtgaag ggacattaca 300  
 atatgactaa cagcaactcc atcacttgag aagtataata gaaaatagct tctaaatcaa 360  
 acttccctca cagtgcctgt tctaccacta caaggactgt gcactaagt aataattttt 420  
 taagattcac tatatgtgat agtatgatat gcattttattt aaaatgcatt agactctctt 480  
 ccattccatc aatactttac aggatggcat ttaatacaga tatttcgtat tccccccact 540  
 gctttttatt tgtacagcat cattaaacac taagctcagt taaggagcca tcagcaacac 600  
 tgaagagatc agtagtaaga attccatttt ccctcatcag tgaagacacc acaaatgaa 660  
 actcagaact atattttctaa gcctgcattt tcaactgatgc ataattttct tagtaattt 720  
 aagagacagt ttttctatgg catctccaaa actgcatgac atcactagtc ttacttctgc 780  
 ttaattttat gagaaggat tcttcatttt aattgctttt gggattactc cacatctttg 840  
 tttatttctt gactaatcag attttcaata gagtgaagtt aaattggggg tcataaaaagc 900  
 attggattga catatggttt gccagcctat ggggtttacag gcattgcccc aacatttctt 960  
 tgagatctat atttataagc agccatggaa ttcttattat gggatgttg caatcttaca 1020  
 ttttatagag gtcatatgca tagttttcat aggtgttttg taagaactga ttgctctcct 1080  
 gtgagtttaag ctatgtttac tactgggacc ctcaagagga ataccactta tgttacactc 1140  
 ctgcactaaa ggcacgtact gcagtgtgaa gaaatgttct gaaaaagggt tatagaaatc 1200  
 tggaaataag aaaggaagag ctctctgtat tctataattg gaagagaaaa aaagaaaaac 1260  
 ttttaactgg aaatgttagt ttgtacttat tgatcatgaa tacaagtata tatttaattt 1320  
 tgaaaaaa

<210> 41  
 <211> 987  
 <212> DNA  
 <213> Human

EP 1 166 798 A1

<400> 41

```

aacagagact ggcacaggac ctcttcattg caggaagatg gtagtgtagg caggtaacat 60
tgagctcttt tcaaaaaagg agagctcttc ttcaagataa ggaagtggta gttatggtgg 120
taaccccccg ctatcagtcg ggatggttgc caccctcctt gctgtaggat ggaagcagcc 180
atggagtggg agggaggcgc aataagacac ccctccacag agcttggcat catgggaagc 240
tggttctacc tcttcctggc tcccttgggt aaaggcctgg ctgggagcct tccttttggg 300
tgtctttctc ttctccaacc aacagaaaag actgctcttc aaagggtggag ggtcttcatg 360
aaacacagct gccaggagcc caggcacagg gctggggggc tggaaaaagg agggcacaca 420
ggaggaggga ggagctggta gggagatgct ggctttacct aaggctctga aacaaggagg 480
gcagaatagg cagaggcctc tccgtcccag gccattttt gacagatggc gggacggaaa 540
tgcaatagac cagcctgcaa gaaagacatg tgttttgatg acaggcagtg tggccgggtg 600
gaacaagcac aggccttgga atccaatgga ctgaatcaga accctaggcc tgccatctgt 660
cagccgggtg acctgggtca attttagcct ctaaaagcct cagtctcctt atctgcaaaa 720
tgaggcttgt tgacacctgt ttgaagggtt gctgagaaaa ttaaagataa gggatcccaa 780
aatagtctac ggccatacca cctgaacgt gcctaatctc gtaagctaag cagggtcagg 840
cctggttagt acctggatgg ggagagtatg gaaaacatac ctgcccgagc ttggagttgg 900
actctgtctt aacagttagc tggcacacag aaggcactca gtaataactt gttgaataaa 960
tgaagttagc atttgggtgtg aaaaaaa

```

<210> 42

<211> 956

<212> DNA

<213> Human

<400> 42

```

cggacgggtg ggcggacgcg tgggtgacag agcaggggcg ctgccgactg ccccaacca 60
ggaaggagcc cctgagtcgg cctgcccctc catccatctg tccggccaga gccggcatcc 120
ttgctgtctt aaagccttaa ctaagactcc cgcccgggct tggccctgtg cagaccttac 180
tcagggggatg tttacctggt gctcgggaag ggagggggag gggccgggga gggggcacgg 240
caggcgtgtg gcagccacac gcaggcggcc agggcgccca gggacccaaa gcaggatgac 300
cacgcacctc cagccactg cctcccccca atgcatttgg aaccaaagtc taaactgagc 360
tcgcagcccc cgcccctcc ctccgctccc catcccgtt agcgtctctg acagatggac 420
gcaggccctg tccagcccc agtgcgctcg ttcgggtccc cacagactgc cccagccaac 480
gagattgctg gaaaccaagt caggccaggt gggcggaaca aagggccagc tgcggcctgg 540
ggggaacgga tgctccgagg actggactgt tttttcaca catcgttggc gcagcgggtg 600
gaaggaaaag cagatgttaa tgatgtgtg gtttacagg tatattttt ataccttaa 660
tgaattaatt cagatgtttt acgcaaggaa ggacttacc agtattact ctgctgtgct 720
tttgatctct gcttaccgtt caagaggcgt gtgcaggcgg acagtcgggt accccatcac 780
tcgcaggacc aaggggggcg ggactgctg ctcacgcccc gctgtgtcct cctccctc 840
ccttccttgg gcagaatgaa ttcgatcgt attctgtggc cgccatctgc gcagggtgg 900
ggtattctgt catttacaca cgtcgttcta attaaaaagc gaattatact ccaaaa

```

<210> 43

<211> 536

<212> DNA

<213> Human

<400> 43

```

aaataaacac ttccataaca ttttgttttc gaagtctatt aatgcaatcc cacttttttc 60
cccctagttt ctaaatgtta aagagagggg aaaaaaggct caggatagtt ttcacctcac 120
agtgttagct gtcttttatt ttactcttgg aaatagagac tccattaggg ttttgacatt 180
ttgggaaccc agttttacca ttgtgtcagt aaaacaataa gatagtttga gagcatatga 240
tetaaataaa gacatttgaa gggtagtttt gaattctaaa agtaggtaat agccaaatag 300
cattctcatc ccttaacaga caaaaactta tttgtcaaaa gaattagaaa aggtgaaaat 360
attttttcca gatgaaactt gtgccacttc caattgacta atgaaatata aggagacaga 420
ctggaaaaag tgggttatgc caccttttaa accctttctg gtaaatatta tggtagctaa 480
agggtggttt ccccggcacc tggacctgga caggtagggg tccgtgggta accagt

```

<210> 44

<211> 1630

<212> DNA

<213> Human

&lt;400&gt; 44

5 ggggaggagac gagtatggaa ccctgaaggt agcaagtcca ggcaactggcc tgaccatccg 60  
 gctccctggg caccaagtec caggcaggag cagctgtttt ccatcccttc ccagacaagc 120  
 tctattttta tcacaaatgac ctttagagag gtctcccagg ccagctcaag gtgtcccact 180  
 atccccctctg gaggggaagag gcaggaaaaat tctcccgggg tccctgtcat gctactttct 240  
 ccatcccagt tcagactgtc caggacatct tatctgcagc cataagagaa ttataaggca 300  
 gtgatttccc ttaggcccag gacttggggc tccagctcat ctgttccttc tggggccatt 360  
 catggcagggt tctgggctca aagctgaact ggggagagaa gagatacaga gctaccatgt 420  
 10 gactttacct gattgccctc agtttggggg tgcttattgg gaaagagaga gacaaagagt 480  
 tacttgttac gggaaatatg aaaagcatgg ccaggatgca tagaggagat tctagcaggg 540  
 gacaggattg gctcagatga cccctgaggg ctcttccagt cttgaaatgc attccatgat 600  
 attaggaagt cgggggtggg tgggtggtgg gggctagtgg ggtttgaatt taggggcccga 660  
 tgagcttggg tacgtgagca ggggtttaag ttagggtctg cctgtatttc tgggtcccctt 720  
 ggaatgtcc ccttcttcag tgtcagacct cagtcccagt gtccatatcg tgcccagaaa 780  
 15 agtagacatt atcctgcccc atcccttccc cagtgcactc tgacctagct agtgcctggt 840  
 gccagtgac ctgggggagc ctggtgcag gccctcactg gtccctaaa ccttgggtggc 900  
 tgtgattcag gtcccagggg gggactcagg gaggaatatg gctgagttct gtagtttcca 960  
 gagtggctg gtagagcctt ctgaggttc agaattattag cttcaggatc agctgggggt 1020  
 atggaattgg ctgaggatca aacgtatgta ggtgaaagga taccaggatg ttgctaaagg 1080  
 tgagggacag tttgggtttg ggacttacca ggggtgatgt agatctggaa cccccaagtg 1140  
 20 aggtctggagg gagttaaggt cagtatggaa gatagggttg ggacagggtg ctttggaaatg 1200  
 aaagagtgc cttagagggc tccttggggc tcagggaatgc tcctgctgct gtgaagatga 1260  
 gaaggtgctt ttactcagtt aatgatgagt gactatattt accaaagccc ctacctgctg 1320  
 ctgggtccct tgtagcacag gagactgggg ctaaggggccc ctcccaggga agggacacca 1380  
 tcaggcctct ggctgaggca gtagcataga ggatccattt ctacctgcat ttcccaggag 1440  
 actagcagga ggcagccttg agaaaccggc agttcccagg ccagcgcctg gctgttctct 1500  
 25 cattgtcact gccctctccc caacctctcc tctaaaccac tagagattgc ctgtgtcctg 1560  
 cctcttgctt cttgtagaat gcagctctgg ccctcaataa atgttccctg cattcatctg 1620  
 caaaaaaaaa

&lt;210&gt; 45

&lt;211&gt; 169

&lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 45

35 tcttttgctt tttagctttt atttttgtat taacaggagt cttattacac ataggtctga 60  
 taaaactggt ttatgatctt cagtctgatt ccagtgtctc ataactagat aacgtatgaa 120  
 ggaaaaacga cgacgaacaa aaaagtaagt gcttggaaga cttagttga

&lt;210&gt; 46

&lt;211&gt; 769

&lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 46

45 tgcaggtcat atttactatc ggcaataaaa ggaagcaaag cagtattaag cagcgggtgga 60  
 atttgtcgct ttcacttttt ataaagtgtc acataaaatg tcatatttcc aaatttataa 120  
 acataactcc agttcttacc atgagaacag catggtgatc acgaaggatc ttcttgaaaa 180  
 aaacaaaaac aaaaacaaaa aacaatgatc tcttctgggt atcacatcaa atgagataca 240  
 aaggtgtact aggcaatctt agagatctgg caacttattt tatatataag gcatctgtga 300  
 ccaagagacg ttatgaatta aatgtacaaa tgtattatgt ataaatgtat taaatgcaag 360  
 cttcatataa tgacaccaat gtctctaagt tgctcagaga tcttgactgg ctgtggccct 420  
 ggccagctcc tttcctgata gtctgattct gccttcata ataggcagct cctgatcatc 480  
 50 catgccagtg aatgagaaaa caagcatgga atatatataac tttaacatta aaaaatgttt 540  
 tattttgtaa taaaatcaaa tttcccattg aaaccttcaa aaactttgca gaatgaggtt 600  
 ttgatatatg tgtacaagta gtaccttctt agtgaagaa aacatcatta tttctgtctg 660  
 cctgcctttt tgtttttaaa aatgaagact atcattgaaa caagtttgtc ttcagtatca 720  
 ggacatgttg acggagagga aaggtaggaa agggttaggg atagaagcc

&lt;210&gt; 47

&lt;211&gt; 2529

&lt;212&gt; DNA



&lt;213&gt; Human

&lt;400&gt; 47

5 tttagttcat agtaatgtaa aaccatttgt ttaattctaa atcaaatac tttcacaaca 60  
 gtgaaaatta gtgactgggt aagggtgtgc actgtacata tcatcatttt ctgactgggg 120  
 tcaggacctg gtcctagtcc acaagggtgg caggaggagg gtggaggcta agaacacaga 180  
 aaacacacaa aagaaggaa agctgccttg gcagaaggat gaggtggtga gcttgccgag 240  
 ggatgggtgg aagggggctc cctgttgggg ccgagccagg agtcccaagt cagctctcct 300  
 10 gccttactta gctcctggca gagggtgagt ggggacctac gaggttcaaa atcaaatggc 360  
 atttggccag cctggcttta ctaacagggt ccagagtgcc ctctgttggc tgagctctcc 420  
 tgggctcact ccatttcatt gaagagtcca aatgattcat tttcctaccc acaacttttc 480  
 attattcttc tggaacccca tttctgttga gtccatctga ctttaagtct ctctccctcc 540  
 actagttggg gccactgcac tgaggggggg cccaccaatt ctctctagag aagagacact 600  
 ccagaggccc ctgcaacttt gcgattttcc agaaggatga aaaaagagca ctcttgagt 660  
 15 ggtgcccagg aatgtttaaa atctatcagg cacactataa agctggtggg ttcttctctac 720  
 caagtggatt cggcatatga accacctact caatacttta tattttgtct gtttaaacac 780  
 tgaactctgg tgttgacagg tacaaaggag aagagatggg gactgtgaag aggggagggg 840  
 ttccctgacc ttccctcaaga tctttgtttc cataaactat gcagtcataa ttgagaaaaa 900  
 gcaatagatg gggcttccca ccatttgttg gttattgctg gggtagcca ggagcagtg 960  
 ggatggcaaa gtaggagaga gggccagagg aaagcccatc tccctccagc tttgggggtct 1020  
 ccagaaagag gctggatttc tgggatgaag cctagaaggc agagcaagaa ctgttccacc 1080  
 20 aggtgaacag tctccctgc ttggtaccat agtccctcaa taagattcag aggaagaagc 1140  
 ttatgaaact gaaaatcaaa tcaaggtatt gggaagaata atttccctc gattccacag 1200  
 gagggaagac cacacaatat cattgtgctg gggctcccca aggccctgcc acctggcttt 1260  
 acaaatcacc aggggttgcc tgcttgccag tcacatgctt ccctggtttt agcacacata 1320  
 caaggagttt tcagggaact ctatcaagcc ataccaaaat cagggtcaca tgtgggtttc 1380  
 25 ccttttctct gcctcttcat aaaagacaac ttggcttctg aggatggtg tcttttgcac 1440  
 gcaagtgggc tgacctgaca aagccccag tttcctgtgg caggttctgg gagaggatgc 1500  
 attcaagctt ctgcagccta ggggacaggg ctgcttgctc agttattact gcctcggagc 1560  
 tccaaatccc accaaagtcc tgactccagg tctttcctaa tgcacagtag tcagtctcag 1620  
 ctctggcagt attctcggct gtatgttctc tggcagagag aggcagatga acatagtttt 1680  
 agggagaaaag ctgatgggaa acctgtgagt taagccacat gtctcaccag gaataattta 1740  
 30 tgccaggaaa ccaggaaagtc attcaagttg ttctctgagg ccaaagacac tgagcacagc 1800  
 ccagagccaa taaaagatct ttgagtctct ggtgaattca cgaagtgacc ccagctttag 1860  
 ctactgcaat tatgattttt atgggacagc aatttcttgc atctctacag aggaagaaga 1920  
 gggggagtggt gaggggaagg aaagagaaca gagcggcact gggatttgaa aggggaacct 1980  
 ctctatctga ggagccccc ctggcttcag aagcaactta ccaaggggta tttaaagaca 2040  
 tgaattttc cagaaatacc atttgggtgca tccctttgtt tctgtaatat taaactcagg 2100  
 35 tgaattata ctctgacagt ttctctcttt ctgcctcttc cctctgcaga gtcaggacct 2160  
 gcagaactgg ctgaaacaag atttcatggt gtcacccatg agagatgact caatgccaa 2220  
 gcttgaagtt atagagtgtt tacagcgttg gcgatattca ggggtcatcg ccaactggtc 2280  
 tcgagttcca aagctctgat gaagaaacaa gactccttga tgtgttactg atccactga 2340  
 ttccaggagt caagattagc caggaagcca aacaacagga gttgggggtg cacgtcacca 2400  
 gtccagagcc ctgccacgga tgtacgcagg agcccagcat taggcaatca ggagccagaa 2460  
 40 catgatcacc agggccacaa ataggaagag gcgtgacagg aactgctcgt ccacataact 2520  
 ggggtgtcc

&lt;210&gt; 48

&lt;211&gt; 1553

&lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 48

5 tttttttttt tttttgattt ctgggacaat taagctttat ttttcatata tatatatatt 60  
 tttcatatata tatatacata catatatataa ggaaacaatt tgcaaattta cacacctgac 120  
 10 aaaaaccatat atacacacat atgtatgcat acacacagac agacacacac acccgaagct 180  
 ctagccaggc ccgttttcca tccctaagta ccattctctc atttgggccc ttctagggtt 240  
 ggggcccctga gcttggtttg tagaagtttg gtgctaatat aacctagct ttaatccca 300  
 tgaaggacac gttagacctc atctttgtct gctcccgcct gcctttcagt tttacgtgat 360  
 ccatcaagag ggctatggga gccaaagtga caggggggat tgaggctaatt tccctgaac 420  
 tgcgaacacag cgcccagctt cctcaccgca ggcacgcgtc ttttcttttt ttttctctga 480  
 15 gacggagtct cgctgtgttg ccagcgtgg agtgacagtgg cacggtctcg gctcactgca 540  
 agctccacct cctggattca taccattctc ctgcttcagc ctcccgagta gctgggacta 600  
 20 taggtgccaa ccactacgcc tagctaattt tttttgtat ttttagtaga gacagggttt 660

caccgtgtta gccaggatgg tctcgtcctg actttgtgat ccgcccgcct cggcctccca 720  
 aagtgtctggg attacaggcg tgagccacca cacctggccc cggcacgtat cttttaagga 780  
 atgacaccag ttcttggcct ctgaccaaag aaaaaatgtc acaggagact ttgaagaggg 840  
 5 agacaggagg gtggtggcag caacactgca gctgctctg gatgctgctg ggggtgctctc 900  
 cggagcgggt gtgaacagcg cacttcaaca tgagcaggcg cctggctccg gtgtgtcctc 960  
 acttcagtgg tgacacctgga tgggtggaagc cagcctttgg ggaggaaaac cagctcagag 1020  
 aggtaccaca gctcagctgc tggcaggagc caggtattta cagccataat gtgtgtaaa 1080  
 aaaaaacacg ttctgcaaga aactctccta cccgctcggg agactggggc tccttgcttg 1140  
 ggatgagctt cactcaacgt ggagatgggt gtggactggg ccctgaaaag cgggccttgc 1200  
 10 agggccaagt gaggtcctca .ggtcctaac ccagtggccc tctgaaaggg ggtgtgcagg 1260  
 cgaggggagc aggaggcttc tctctagtcc ctttgagggc ttggtgtgag agaagagtga 1320  
 gcagggagct gggaatggtc caggcaggga agggagctga agtgattcgg ggctaattgc 1380  
 tcagatcgat gtatttctct ccctgtgtct cgggagccct cttgtcaccg ctgctgccct 1440  
 gcaggaggcc catctcttct gggagcttat ctgacttaac ttcaactaca agttcgctct 1500  
 tacgagaccg ggggtagcgt gatctcctgc ttccctgagc gctgcacgg cag

<210> 49  
 <211> 921  
 <212> DNA  
 <213> Human

<400> 49

ctgtggtccc agctactcag gaggctgagg cgggaggatt gcttgagccc aggagtggga 60  
 tgttgcatgt agccaagatc gcaccattgc cctccactct gggccacgga gcaataccct 120  
 gtctcagaaa acaacaaca aaaagcagaa acgctgaagg ggtcggttta cgggaaaacc 180  
 25 gcctgtcaga acacttggct actcctaccc cagatcagtg gacctgggaa tgagggttgg 240  
 tcccgggagg cttttctcca agctgttgcc accagaccgg ccatgggaac cctggccaca 300  
 gaagcctccc ggggagttag ccagagcctg gaccgctgtg ctgatgtgtc tggggtggag 360  
 ggaggggtggg gagtgtgcaa ggggtgtgtg gtgcccgggg ggtgttcatt ggcaagcatg 420  
 tgcgtgcttg tgtgtgtgctg tgcctctccc ctgcagcctg cgggtgtatc tccctccagc 480  
 cccttcgcca ccttctgagc attgtctgtc cacgtgagac tgcccagaga cagcagagct 540  
 ccacgtgggt ttaaggggag acctttccct ggacctgggg gtctcgccgt atctcatgac 600  
 30 caggtgtctaa atgaccggac atgcatcacc tgcctttcga tgaccaacct ccctgtcccc 660  
 gtcccgtcga cctgccccg tggcgtctca cggtgatgcc tgctcctgac attggtgttc 720  
 actgtagcaa actacattct ggtggtgaa tttcatgtac atgtgtggca tgtggaaaat 780  
 ttcaataaaa atggacttga tttagaaagc caaaaagctg tgtgtcctt ccagcacgga 840  
 tactttgacc tcttgccctac aacccttccc ttgggtccga ggctggttagc tttgttcact 900  
 tcagatgggt gggggcgggt g

<210> 50  
 <211> 338  
 <212> DNA  
 <213> Human

<400> 50

atgatctatc tagatgcctt accgtaaaa caaacacaaa aaccctactg actcattccc 60  
 tcccttccag atattacccc atttctctac ttcccattgt agccaaactt tccaaaaatt 120  
 catgttctgt cttcatttcc tcatgttcaa cccaccctgt cttagctacc accctcagt 180  
 45 aacgacctag cctgggtaga aacaaatgtc agcatgatac catactcaat gatccttcgt 240  
 cactgttgtc attgtcatca ttccatggcc ttactttccc tctcagcgcc atttgctaca 300  
 gtaagaaact ttctttcttg aattcttggg tctcttgg

<210> 51  
 <211> 1191  
 <212> DNA  
 <213> Human

<400> 51

ctgacaaagca ggtaaacgag ctttgtacaa acacacacag accaacaacat ccggggatgg 60  
 ctgtgtgttg ctagagcaga ggctgattaa acactcagtg tgttggctct ctgtgccact 120  
 cctggaaaat aatgaattgg gtaaggaaca gtaataaaga aaatgtgcct tgctaactgt 180  
 55 gcacattaca acaagagct ggagctcct gaaggaaaag ggcttgtgcc gctgccgttc 240  
 aaacttgtca gtcaactcat gccagcagcc tcagcgtctg cctccccagc acaccctcat 300

tacatgtgtc tgtctggcct gatctgtgca tctgctcgga gacgctectg acaagtctggg 360  
 aatttctcta tttctccact ggtgcaaaga gcggtattct cctgcttct cttctgtcac 420  
 ccccgctcct ctccccagg aggtcctctg atttatggta gctttggact tgcttccccg 480  
 5 tctgactgtc cttgacttct agaattggaag aagctgagct ggtgaaggga agactccagg 540  
 ccatcacaga taaaagaaaa atacaggaag aaatctcaca gaagcgtctg aaaatagagg 600  
 aagacaaact aaagcaccag catttgaaga aaaaggcctt gagggagaaa tggcttctag 660  
 atggaatcag cagcggaaaa gaacaggaag agatgaagaa gcaaaatcaa caagaccagc 720  
 accagatcca ggttctagaa caaagtatcc tcaggcttga gaaagagatc caagatcttg 780  
 aaaaagctga actgcataat tcaacgaagg aagaggccat tttaaagaaa cttaagtcaa 840  
 10 ttgagcggac aacagaagac attataagat ctgtgaaagt ggaagagaa gaaagagcag 900  
 aagagtcaat tgaggacatc tatgctaata tccctgacct tccaaagtcc tacatacctt 960  
 ctagggttaag gaaggagata aatgaagaaa aagaagatga tgaacaaaat aggaaagctt 1020  
 tatatgccat ggaaattaaa gttgaaaaag acttgaagac tggagaaagt acagttctgt 1080  
 cttccaatac ctctggccat cagatgactt taaaagggtac aggagtaaaa gtttaagatg 1140  
 atgggcaaaa gtccagtgtat ttcagtaaaag tgctaatac aagttggagg t

<210> 52  
 <211> 1200  
 <212> DNA  
 <213> Human

<400> 52

aacagggact ctactctat caacccagg ctggagtccg gtgcgcccac cctggctccc 60  
 tgcaacctcc gctcccagg ctcaagcaac tctcctgcct cagtcgctct agtagctggg 120  
 actacaggca cacaccacca tgcccagcca atttttgcat tttttgtaga gacagggttt 180  
 25 cgccttctgt ccaggccggc atcatatact ttaaatcatg ccagatgac ttaatacct 240  
 aatacaatat atcagggttg tttaaaaata attgcttttt tattattttt gcatttttgc 300  
 accaacctta atgctatgta aatagttgtt atactgttgc ttaacaacag tatgacaatt 360  
 ttggcttttt ctttgtatta ttttgtattt ttttttttta ttgtgtggtc tttttttttt 420  
 ttctcagtgt tttcaattcc tcttgggtg aatccatgga tgcaaaaccc acagatatga 480  
 agggctggct atatatgcat tgatgattgt cctattatat tagttataaa gtgtcatrta 540  
 30 atagttagtg aaagttagtg tacagtggaa agagttagtg aaaacataaa catttgacc 600  
 tttcaagaaa ggttagcttg tgaaagtttt cacttcaaaa ctatgtccca gtcagggttc 660  
 tgctactaat tagctataat ctttgacaaa attacatcac ctttgagtct cagttgctc 720  
 acctgtaaaa tgaaagaaact ggatactctc taaggctact tccagccctg tcattctata 780  
 actctgttat gctgaggaag aaattcacat tgtgttaact gtatgagtca aactgaaaat 840  
 gattattaaa gtgggaaaaa gccaatgtct tctcttagaa agctcaacta aatttgagaa 900  
 35 gaataatott ttcaattttt taagaattta aatattttta agggtttgac ctatttattt 960  
 agagatgggg tctcactctg tcacccagac tggagtacag tggcacaatc atagctcact 1020  
 gctgcctcaa attcatgggc tcaagtgate ctctgcctc tgccctccaga gtagctgcga 1080  
 ctatgggcat gtgccaccac gcttggctaa catttgtatt gacctattta tttattgtga 1140  
 tttatatctt tttttttttt tctttttttt ttttttacia aatcagaaat acttattttg 1200

<210> 53  
 <211> 989  
 <212> DNA  
 <213> Human

<400> 53

aagccaccac tcaaaacttc ctatacattt tcacagcaga gacaagtga cttttatttt 60  
 tatgcctttc ttcctatgtg tatttcaagt ctttttcaaa acaaggcccc aggactctcc 120  
 gattcaatta gtccttgggc tggctgactg tgcaggagtc caggagcct ctacaaatgc 180  
 agagtgactc tttaccaaca taaacctag ataatgcaa aaagcaggac ccttctccca 240  
 45 ggaatgtgcc atttcagatg cacagcacc atgcagaaaa gctggaattt tccttggaac 300  
 cgactgtgat agagggtgctt acatgaacat tgctactgtc tttctttttt tttgagacag 360  
 gtttcgcttg tgcccaggct gagtgaatg cgtgatctca ctactgcaa tccacctcc 420  
 50 aggttcaagc atttctctgc tcagcctcct agtagctggg ttacaggcac tgccaccatg 480  
 ccggctaatt ttgtattttt gtagagatgg atttctccat ttggtcaggc ggtctcgaa 540  
 cccaacctca gtgatctgcc acctcagcct cctaagtgtt ggattacagg atgagccacc 600  
 cgaccggcca ctactgtctt tcttggacct ttccagtttc gaagataaag aggaaataat 660  
 ttctctgaag tacttgataa aatttccaaa caaaacacat gtccacttca ctgataaaaa 720  
 atttaccgca gtttggcacc taagagtatg acaacagcaa taaaaagtaa tttcaagag 780  
 55 ttaagatttc ttcagcaaaa tagatgattt acatcttcaa gtcctttttg aaatcagtta 840  
 ttaatatatt tcttctctca ttccatctg aatgactgca gcaatagttt tttttttttt 900

tttttttttt ttgcgagatg gaatctcgct ctgtcgccca gcgggagtg actggcgcaa 960  
gcccggctca ccgcaatctc tgccaccg

<210> 54  
<211> 250  
<212> DNA  
<213> Human

<400> 54

catttcccca ttggtcctga tgttgaagat ttagttaag aggctgtaag tcaggttcga 60  
gcagaggcta ctacaagaag tagggaatca agtccctcac atgggctatt aaaactaggt 120  
agtgggtggag tagtgaaaaa gaaatctgag caacttcata acgtaactgc ctttcaggga 180  
aaagggcatt ctttaggaac tgcattctggt aaccacaccc ttgatccaag agctagggaa 240  
acttcagttg

<210> 55  
<211> 2270  
<212> DNA  
<213> Human

<400> 55

gcgccccga gcagcgccc cgcctctccg gccttctccg ccgggacctc gagcgaaaga 60  
ggcccgcgcg ccgcccagcc ctgcctccc tgcccaccgg gcacacggcg ccgccacccc 120  
gaccccgctg cgcacggcct gtccgctgca caccagcttg ttggcgctct cgtcgccgcy 180  
ctcgccccgg gctactcctg cgcgccacaa tgagctcccg catcgccagg gcgctcgcc 240  
tagtcgtcac ccttctccac ttgaccaggc tggcgctctc cactgcccc gctgcctgcc 300  
actgccccct ggaggcgccc aagtgcgcgc cgggagtcgg gctgggccgg gacggctgcy 360  
gctgctgtaa ggtctgcgcc aagcagctca acgaggactg cagcaaaacg cagccctgcy 420  
accacaccaa ggggctggaa tgcaacttcg gcgccaagtc caccgctctg aaggggatct 480  
gcagagctca gtcagagggc agaccctgtg aatataactc cagaatctac caaaacgggg 540  
aaagtgttcca gcccaactgt aaacatcagt gcacatgtat tgatggcgcc gtgggctgca 600  
ttctctgtg tccccagaa ctatctctcc ccaacttggg ctgtcccaac cctcggtcgg 660  
tcaaagttac cgggcaagtgc tgcgaggagt gggctctgta cgaggatagt atcaaggacc 720  
ccatggagga ccaggacggc ctctctggca aggagctggg attcgatgcc tccgaggtgg 780  
agttgacgag aaacaatgaa ttgattgcag ttggaaaagg cagctcactg aagcggtctc 840  
ctgtttttgg aatggagcct cgcattcctat acaacccttt acaaggccag aaatgtattg 900  
ttcaaaacac ttcatgttcc cagtgtctca agacctgtg aactggatc tccacacgag 960  
ttaccaatga caacctgag tgccgcttg tgaagaaac ccgatttgt gaggtgcggc 1020  
cttgtggaca gccagtgtac agcagcctga aaaagggcaa gaaatgcagc aagaccaaga 1080  
aatccccga accagtcagg ttactttacg ctggatgttt gagtgtgaag aaataccggc 1140  
caaagtactg cggttcctgc gtggacggcc gatgctgcac gcccagctg accaggactg 1200  
tgaagatgcy gttccgctgc gaagatgggg agacatttcc caagaacgtc atgatgatcc 1260  
agtcctgcaa atgcaactac aactgcccgc atgccaatga agcagcggtt cccttctaca 1320  
ggctgttcaa tgacattcac aaatttaggg actaaatgct acctgggttt ccagggcaca 1380  
cctagacaaa caaggagaa gagtgtcaga atcagaatca tggagaaaat gggcgggggg 1440  
gggtgtgggt atgggactca ttgtagaaag gaagccttgc tcattcttga ggagcattaa 1500  
ggatatttca aactgccaag ggtgctggtg cggatggaca ctaatgcagc cagcattgga 1560  
gaatactttg cttcatagta ttggagcaca tgttactgct tcattttgga gcttgtggag 1620  
ttgatgactt tctgttttct gtttgtaaa ttttgcata gcatatttct tctaggcttt 1680  
tttcttttgg gggttctaca gtctgtaaa agataataag attagttgga cagttaaag 1740  
cttttattcg tcttttgaca aaagtaaatg ggagggcatt ccatcccttc ctgaaggggg 1800  
acactccatg agtgtctgtg agaggcagct atctgcactc taaactgcaa acagaaatca 1860  
gggtgtttta gactgaatgt tttatttacc aaaatgtagc ttttggggag ggaggggaaa 1920  
tgtaatactg gaataatttg taaatgattt taattttata ttcagtgaag agattttatt 1980  
tatggaatta accatttaat aaagaaatat ttacctaata tctgagtgtg tgccattcgg 2040  
tatttttaga ggtgctccaa agtcattagg aacaacctag ctcacgtact caattattca 2100  
aacaggactt attgggatac agcagtgaat taagctatta aaataagata atgattgctt 2160  
ttataccttc agtagagaaa agtctttgca tataaagtaa tgtttaaaaa acatgtattg 2220  
aacacgacat tgtatgaagc acaataaaga ttctgaagct aaaaaaaaaa

<210> 56  
<211> 1636  
<212> DNA  
<213> Human

&lt;400&gt; 56

5 cttgaatgaa gctgacacca agaaccgcgg gaagagcttg ggcccaaagc aggaaaggga 60  
 agcgctcgag ttggaaagga accgctgctg ctggccgaac tcaagcccgg gcgccccac 120  
 cagtttgatt ggaagtccag ctgtgaaacc tggagcgctg ccttctcccc agatggctcc 180  
 tggtttgctt ggtctcaagg acactgcac gtcaaactga tccccggcc gttggaggag 240  
 cagttcatcc ctaaagggtt tgaagccaaa agccgaagta gcaaaaatga gacgaaagg 300  
 cggggcagcc caaaagagaa gacgctggac tgtggtcaga ttgtctgggg gctggccttc 360  
 10 agcccgtagc cttccccacc cagcaggaag ctctgggcac gccaccaccc ccaagtggcc 420  
 gatgtctctt gccctggtct tgctacggga ctcaacgatg ggcagatcaa gatctgggag 480  
 gtgcagacag ggctctgctt tttgaatctt tccggccacc aagatgtcgt gagagatctg 540  
 agcttcacac ccagtggcag tttgattttg gtctccgctg caccggataa gactcttcgc 600  
 atctgggacc tgaataaaca cggtaaacag attcaagtgt tatcgggcca cctgcagtgg 660  
 gtttactgct gttccatctc ccagactgc agcatgctgt gctctgcagc tggagagaag 720  
 15 tcggtctttc tatggagcat gaggtcttac acgttaattc ggaagctaga gggccatcaa 780  
 agcagtgttg tctcttgtga cttctcccc gactctgccc tgcttgtcac ggcttcttac 840  
 gataccaatg tgattatgtg ggacccttac accggcgaaa ggctgaggtc actccaccac 900  
 acccaggttg accccgcat ggatgacagt gacgtccaca ttagctcact gagatctgtg 960  
 tgctctctc cagaaggctt gtacctggcc acggtggcag atgacagact cctcaggatc 1020  
 tgggcccctg aactgaaac tccattgca tttgctccta tgaccaatgg gctttgtctg 1080  
 20 acattttttc cacatggtgg agtcattgcc acagggacaa gagatggcca cgtccagtcc 1140  
 tggcagctc ctagggtcct gtctcactg aagcacttat gccggaaagc ccttcgaagt 1200  
 ttcttaacaa cttaccaagt cctagcactg ccaatcccca agaaaatgaa agagttcctc 1260  
 acatacagga ctttttaagc aacaccacat cttgtgcttc tttgtagcag ggtaaatcgt 1320  
 cctgtcaaaq ggagtgtctg gaataatggg ccaaactctt ggtcttgcag tgaatatgca 1380  
 tttctttggg atttgtgaata gaatgtagca aaaccagatt ccagtgtaca taaaagaatt 1440  
 25 tttttgtctt taaatagata caaatgtcta tcaactttaa tcaagtgtga acttatattg 1500  
 aagacaattt gatacataat aaaaaattat gacaatgtcc tgggaaaaaa aaaatgtaga 1560  
 aagatggtga agggtgggat ggatgaggag cgtggtgacg ggggcctgca gcgggttggg 1620  
 gacctgtgc tgcgtt

&lt;210&gt; 57

&lt;211&gt; 460

&lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 57

35 ccatgtgtgt atgagagaga gagagattgg gagggagagg gagctcacta gcgcatatgt 60  
 gcctccaggg ggctgcagat gtgtctgagg gtgagcctgg tgaaagagaa gacaaaagaa 120  
 tggaatgagc taaagcagcc gcctgggggtg ggaggccgag cccatttgta tgcagcaggg 180  
 ggcaggagcc cagcaaggga gcctccattc ccaggactct ggaggagct gagaccatcc 240  
 atgcccgag agccctccct cacactccat cctgtccagc cctaattgtg caggtgggga 300  
 aactgaggct gggaagtcac atagcaagtg actggcagag ctgggactgg aaccaacca 360  
 40 gcctcctaga ccacggttct tcccatcaat ggaatgctag agactccagc caggtgggta 420  
 ccgagctoga attcgtaatc atggtcatag ctgtttcctg

&lt;210&gt; 58

&lt;211&gt; 1049

&lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 58

50 atctgatcaa gaatacctgc cctgggtcact ctgcggatgt ttctgtccac ttgttcacat 60  
 tgaggaccaaa gatataccttt tttacagagg cacttggtcg gtctaacaca gacacctcca 120  
 tgacgacatg ctggctcaca ttttgagtt ctgcagaagt cccccccca gcctggacta 180  
 cagcagcact ttcccgtagg ggtgcagtag ccgtttcgac agagcctgga gcactctgaa 240  
 gtcagtgtct gtgcagggtg taccgtggct ctgcattcct caggcatata aggtcttttg 300  
 ggatctacaa ttttgtagag ttttccattg tgagtctggg tcatactttt actgcttgat 360  
 aaaatgtaaa cttcacctag ttcattctct ccaaatccca agatgtgacc ggaagtag 420  
 cctctacagc acccactagt gccgacacag agtgggtttt cttgccactg ctttgtcaca 480  
 ggactttgct ggagagttag gaaattccca ttacgatctc caaacacgta gcttccatac 540  
 55 aatctttctg actggcagcc ccggtataca aatccacca ccaaaggacc attactgaat 600  
 ggcttgaatt ctaaaagtga tggctcactt tcataatctt tcccccttat tatctgtaga 660

attctggctg atgatctgtt tttccattg gagtctgaac acagtatcgt taaattgatg 720  
 tttatatcag tgggatgtct atccacagca catctgcctg gatcgtggag cccatgagca 780  
 aacacttcgg ggggctgggt ggtgctgttg aagtgtgggt tgctccttgg tatggaataa 840  
 5 ggcacgttgc acatgtctgt gtccacatcc agccgtagca ctgagcctgt gaaatcactt 900  
 aacccatcca tttcttccat atcatccagt gtaatcatcc catcaccaag aatgatgtac 960  
 aaaaaccgt cagggccaaa gagcagttgc cctccagat gctttctgtg gagttctgca 1020  
 acttcaagaa agactctggc tgttctcaa

<210> 59  
 <211> 747  
 <212> DNA  
 <213> Human

<400> 59

tttttcaaat cacatatggc ttctttgacc ccatcaaata actttattca cacaaacgtc 60  
 ccttaattta caaagcctca gtcattcata cacattaggg gatccacagt gttcaaggaa 120  
 cttaaatata atgtatcata ccaaccaag taaaccaagt acaaaaaata ttcataataa 180  
 gttgttcaca cgtaggctct agattaccag cttctgtgca aaaaaaggaa atgaagaaaa 240  
 atagatttat taactagtat tggaaactaa ctttgtgcct ggcttaaaac ctccctcacg 300  
 20 ctgctctgtc ccacacaaat gtttaagaag tcaactgcaat gtactccccg gctctgatga 360  
 aaagaagccc ctggcacaaa agattccagt gcccctgaag aggtccctt cctcctgtgg 420  
 gctctcctag aaaaccagcg ggacggcctc cctgctgata ccgtctataa ccttaggggg 480  
 ccctcgggca ggcaacggca gtggactcat ctcggtgatg gctgtagatg ctaacactgg 540  
 ccaattcaat gccacaccta ctggttacct tttgagggca tttctccaga cagaagcccc 600  
 25 ttgaagccta gtagggcgag gatcagagat acacccgtgt ttgtctcgaa gggctccaca 660  
 gcccagtacg acatgcttgc agaagtagta tctctggact tctgcctcca gtcgaccggc 720  
 cgcgaattta gtagtaatag cggccgc

### Claims

1. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems.
2. Pharmaceutical compositions comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems.
3. Pharmaceutical compositions comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium.
4. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
5. Pharmaceutical compositions comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
6. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems.
7. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as

compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.

8. Pharmaceutical compositions comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

9. Pharmaceutical compositions according to claims 1-8 which are intended for simultaneous or separate sequential therapeutical application.

10. Pharmaceutical compositions according to claims 1-8 which comprise as compound I at least one of

- a) compounds which inhibit receptor tyrosine kinase activity,
- b) compounds which inhibit ligand binding to receptors,
- c) compounds which inhibit activation of intracellular signal pathways of the receptors,
- d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

11. Pharmaceutical compositions according to claims 1-8 which comprise as compound II at least one of


- g) compounds which inhibit receptor tyrosine kinase activity,
- h) compounds which inhibit ligand binding to receptors,
- i) compounds which inhibit activation of intracellular signal pathways of the receptors,
- j) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- k) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- l) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

12. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

13. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II Seq. ID Nos. 34a

14. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35 and/ or scFv-tTF conjugate.

15. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one small molecule of general formula I



I,

in which

r


has the meaning of 0 to 2,

n

has the meaning of 0 to 2;

R<sub>3</sub> und R<sub>4</sub>

- a) each independently from each other have the meaning of lower alkyl,
- b) together form a bridge of general partial formula II,




II,

wherein the binding is via the two terminal C- atoms,  
and

m

has the meaning of 0 to 4; or

- c) together form a bridge of partial formula III



III,

wherein one or two of the ring members T<sub>1</sub>, T<sub>2</sub>, T<sub>3</sub>, T<sub>4</sub> has the meaning of nitrogen, and each others have the meaning of CH, and the binding is via the atoms T<sub>1</sub> and T<sub>4</sub>;

G

has the meaning of C<sub>1</sub> - C<sub>6</sub> - alkyl, C<sub>2</sub> - C<sub>6</sub> - alkylene or C<sub>2</sub> - C<sub>6</sub> - alkenylene; or C<sub>2</sub> - C<sub>6</sub> - alkylene or C<sub>3</sub> - C<sub>6</sub> - alkenylene, which are substituted with acyloxy or hydroxy; -CH<sub>2</sub>-O-, -CH<sub>2</sub>-S-, -CH<sub>2</sub>-NH-, -CH<sub>2</sub>-O-CH<sub>2</sub>-, -CH<sub>2</sub>-S-CH<sub>2</sub>-, -CH<sub>2</sub>-NH-CH<sub>2</sub>-, oxa (-O-), thia (-S-) or imino (-NH-),


A, B, D, E and T

independently from each other have the meaning of N or CH, with the proviso that not more than three of these Substituents have the meaning of N,




Q has the meaning of lower alkyl, lower alkyloxy or halogene,  
 $R_1$  and  $R_2$  independently from each other have the meaning of H or lower alkyl,  
 X has the meaning of imino, oxa or thia;  
 Y has the meaning of hydrogen, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and  
 Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if more than one rest Z is present ( $m \geq 2$ ), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single or double bonds; or an N-oxide of said compound, wherein one ore more N-atoms carry an oxygene atom, or a salt thereof,

and/or a compound of genaral formula IV






in which

A has the meaning of group  $=NR^2$ ,  
 W has the meaning of oxygen, sulfur, two hydrogen atoms or the group  $=NR^8$ ,  
 Z has the meaning of the group  $=NR^{10}$  or  $=N-$ ,  $-N(R^{10})-(CH_2)_q-$ , branched or unbranched  $C_{1-6}$ -Alkyl or is the group



or A, Z and  $R^1$  together form the group





m, n and o

q

$R_a, R_b, R_c, R_d, R_e, R_f$

has the meaning of 0 - 3,

has the meaning of 1 - 6,

independently from each other have the meaning of hydrogen,  $C_{1-4}$  alkyl or the group  $=NR^{10}$ , and/ or  $R_a$  and/ or  $R_b$  together with  $R_c$  and/ or  $R_d$  or  $R_e$  together with  $R_f$  form a bound, or up to two of the groups  $R_a-R_f$  form a bridge with each up to 3 C-atoms with  $R^1$  or  $R^2$ ,

X

has the meaning of group  $=NR^9$  or  $=N-$ ,

Y

has the meaning of group  $-(CH_2)_p$ ,

p

has the meaning of integer 1-4,

$R^1$

has the meaning of unsubstituted or optionally substituted with one or more of halogene,  $C_{1-6}$ -alkyl, or  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,

$R^2$


has the meaning of hydrogen or  $C_{1-6}$ -alkyl, or form a bridge with up to 3 ring atoms with  $R_a-R_f$  together with Z or  $R^1$ ,

$R^3$

has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally substituted with one or more of fur halogen,  $C_{1-6}$ -alkyl,  $C_{1-6}$ -alkoxy or hydroxy,

$R^4, R^5, R^6$  and  $R^7$


Independently from each other have the meaning of hydrogen, halogene or  $C_{1-6}$ -alkoxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogene, or  $R^5$  and  $R^6$  together form the group



$R^8, R^9$  and  $R^{10}$

independently from each other have the meaning of hydrogen or  $C_{1-6}$ -alkyl, as well as their isomers and salts,



and/ or a compound of general formula V




V,

in which


R<sup>1</sup> has the meaning of group



in which R<sup>5</sup> is chloro, bromo or the group -OCH<sub>3</sub>,



in which R<sup>7</sup> is -CH<sub>3</sub> or chloro,




in which R<sup>8</sup> is -CH<sub>3</sub>, fluoro, chloro or -CF<sub>3</sub>

in which R<sup>4</sup> is fluoro, chloro, bromo, -CF<sub>3</sub>, -N=C, -CH<sub>3</sub>, -OCF<sub>3</sub> or -CH<sub>2</sub>OH

in which R<sup>6</sup> is -CH<sub>3</sub> or chloro

R<sup>2</sup> has the meaning of pyridyl or the group



and

10  $R^3$  has the meaning of hydrogen or fluoro, as well as their isomers and salts.

16. Pharmaceutical compositions according to claim 15 which comprise as compound I and/ or II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate

15 17. Pharmaceutical compositions according to claims 1-16 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35 and/ or scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate sTie2, mAB 4301-42-35 and/ or scFv-tTF conjugate, with the proviso that compound I is not identically to compound II.

20 18. Pharmaceutical compositions according to claims 1-17 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35 and/ or scFv-tTF conjugate.

25 19. Pharmaceutical compositions according to claims 1-17 which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate.

20. Pharmaceutical compositions according to claims 1-17 which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35.

30 21. Use of pharmaceutical compositions according to claims 1-20, for the production of a medicament for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.




Fig. 1



European Patent  
Office

# PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

EP 00 25 0194

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	WO 98 35958 A (NOVARTIS ERFINDUNGEN VERWALTUN ; CIBA GEIGY AG (CH); TRAXLER PETER) 20 August 1998 (1998-08-20) * abstract * * page 1, paragraph 1 *	1-15, 21	A61K45/06
A	KOBLIZEK, THOMAS I. ET AL: "Angiopoietin-1 induces sprouting angiogenesis in vitro" CURR. BIOL. (1998), 8(9), 529-532 , XP000972727 * page 531, column 1, paragraph 2 *	1-21	
A	SCHLAEPI, JEAN-MARC ET AL: "Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors." CANCER AND METASTASIS REVIEWS, (1999) VOL. 18, NO. 4, PP. 473-481. PRINT. , XP000972749 * page 477, column 2, paragraph 2 - page 478, column 1, paragraph 1 *	1-21	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			A61K
INCOMPLETE SEARCH			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims</p> <p>Claims searched completely</p> <p>Claims searched incompletely</p> <p>Claims not searched</p> <p>Reason for the limitation of the search</p> <p>see sheet C</p>			
Place of search		Date of completion of the search	Examiner
THE HAGUE		12 January 2001	Leherte, C
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons</p> <p>* member of the same patent family, corresponding document</p>			

EPO FORM 1503 03 82 (P04007)



European Patent  
Office

INCOMPLETE SEARCH  
SHEET C

Application Number  
EP 00 25 0194

Claim(s) searched completely:  
17-20

Claim(s) searched incompletely:  
1-16, 21

Reason for the limitation of the search:

Present claims 1-16,21 relate to compounds defined by reference to desirable characteristics or properties, namely :

- " agents which modulates the biological function of one or several of the VEGF/VEGF receptor systems",
- " agents which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems",
- " agents which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems",
- " agents which are targeted to the endothelium",
- " agents which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems",
- " agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of the Angiopoietin/Tie receptor systems",
- " compounds which inhibit receptor tyrosine kinase activity",
- " compounds which inhibit ligand binding to receptors",
- " compounds which inhibit activation of intracellular signal pathways of the receptors",
- " compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor systems",
- " delivery systems, which target cytotoxic agents or coagulation-inducing agents to the endothelium",
- "delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis",
- " compounds of general formula I, IV or V".

The claims cover all compounds having those characteristics, properties or formulas, whereas the application provides support within the meaning of Article 84 EPC and/or disclosure within the meaning of Article 83 EPC for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 84 EPC). An attempt is made to define the compounds by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the pharmaceutical compositions mentioned in the claims 17-20, with due regard to the therapeutic applications mentioned in claim 21.

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 25 0194

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

12-01-2001

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9835958 A	20-08-1998	AU 6621898 A	08-09-1998
		BR 9807685 A	21-03-2000
		CN 1251097 T	19-04-2000
		CZ 9902853 A	17-11-1999
		EP 0970070 A	12-01-2000
		NO 993888 A	11-10-1999
		PL 335113 A	10-04-2000
		SK 109699 A	13-03-2000
		ZA 9801155 A	13-08-1998

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**